P X V X -C V -[ADDRESS_1089725] u d y  Pr ot o c ol  d o c u m e nt  a n d  all i nf or m ati o n  pr o vi d e d t o  y o u r el at e d t o t his 
pr ot o c ol  ar e t h e  c o nfi d e nti al  a n d  pr o pri et ar y i nf or m ati o n  of  E m er g e nt  Tr a v el  H e alt h I n c. ( “ S p o ns or ”)  a n d  ar e s u bj e ct t o t h e t er ms  of t h e  C o nfi d e nti al  Dis cl os ur e  A gr e e m e nt  b et w e e n  y o u a n d  E m er g e nt  Tr a v el  H e alt h I n c.  
 
 
B y si g ni n g  b el o w, I  h er e b y  c o nfir m t h e f oll o wi n g: 
I  a gr e e t o  a bi d e  b y t h e t er ms  of t h e  E m er g e nt  Tr a v el  H e alt h I n c.  C o nfi d e nti al  Dis cl os ur e 
A gr e e m e nt.  
I  h a v e r e a d t his  pr ot o c ol i n its  e ntir et y  a n d I  a gr e e t o  c o n d u ct t h e st u d y  a c c or di n g t o t his 
pr ot o c ol.  A n y  c h a n g es i n  pr o c e d ur e  will  o nl y  b e  m a d e if  n e c ess ar y, t o  pr ot e ct t h e s af et y, ri g hts, or  w elf ar e  of s u bj e cts.  
I  a gr e e t o  c o m pl y  wit h t h e  c urr e nt I nt er n ati o n al  C o nf er e n c e  o n  H ar m o ni z ati o n  Tri p artit e 
G ui d eli n e  o n  G o o d  Cli ni c al  Pr a cti c e i n  a d diti o n t o t h e  a p pr o pri at e  F D A  C o d e  of  F e d er al R e g ul ati o ns ( C F Rs)  a n d st at e  a n d l o c al r e g ul ati o ns. 
I  a gr e e t o  c o n d u ct t h e st u d y i n  p ers o n  or t o s u p er vis e t h e st u d y. 
I  a gr e e t o  e ns ur e t h at  all  w h o  assist  m e i n t h e  c o n d u ct  of t h e st u d y  h a v e  a c c ess t o t h e st u d y 
pr ot o c ol, i n cl u di n g  a n y  a m e n d m e nts t h er et o,  a n d  ar e  als o  m a d e  a w ar e  of t h eir r es p o nsi biliti es i n m e eti n g t h e f or e g oi n g  o bli g ati o ns. 
 
 
 
P ri n ci p al I n v esti g at o r 
( Pri nt  Na m e)     
Titl e     
Si g n at u r e   D at e  
 
Sit e t o s e n d si g n e d  ori gi n al t o  E m er g e nt  Tr a v el  H e alt h I n c.  a n d t o  k e e p  a  c o p y f or fil es. 
P X V X -C V -[ADDRESS_1089726] u d y  t o 
Ass ess  t h e S af et y  a n d  I m m u n o g e ni cit y  of P X V X 0 3 1 7  ( C hi k u n g u n y a 
Vir us -Vir us  Li k e  P arti cl e  V a c ci n e [ C HI K V -V L P],  u n a dj u v a nt e d  or al u m - a dj u v a nt e d) 
SI T E S  M ulti - c e nt er,  u p t o  5  U S sit es 
O B J E C TI V E S  T h e  g o al   of  t his  tri al  is  t o  e v al u at e  t h e  s af et y,  t ol er a bilit y  a n d 
i m m u n o g e ni cit y   of   8   f or m ul ati o n/s c h e d ul e   c o m bi n ati o ns   of 
P X V X [ADDRESS_1089727]   o n e   or    m or e   f or m ul ati o n(s)   f or   f urt h er d e v el o p m e nt.  O n e  f or m ul ati o n  a n d  d osi n g  s c h e d ul e  will  b e  f urt h er e v al u at e d i n  a n  o p e n -l a b el  Gr o u p  9. 
I m m u n o g e ni cit y  O bj e cti v es  
Pri m ar y  
   T o  ass ess t h e i n d u cti o n  of  a nti- c hi k u n g u n y a  vir us  ( C HI K V) 
n e utr ali zi n g  a nti b o d y r es p o ns es  b y  diff er e nt f or m ul ati o ns 
a n d s c h e d ul es,  as  m e as ur e d  at  [ADDRESS_1089728] 
i nj e cti o n ( D a y  5 7). 
S e c o n d ar y  
   T o  ass ess t h e  ki n eti cs  of i n d u cti o n  of  a nti- C HI K V 
n e utr ali zi n g  a nti b o d y r es p o ns es  b y  diff er e nt f or m ul ati o ns 
a n d  s c h e d ul es,  as  m e as ur e d fr o m  [ADDRESS_1089729] 
i nj e cti o n ( D a y  8) t o  [ADDRESS_1089730] i nj e cti o n ( D a y  5 7). 
 
   T o  ass ess t h e  diff er e n c e i n  p ersist e n c e  of  n e utr ali zi n g 
a nti b o d y r es p o ns es i n d u c e d  b y  diff er e nt f or m ul ati o ns  a n d s c h e d ul es,  as  m e as ur e d  u p  t o  [ADDRESS_1089731] 
i nj e cti o n ( D a y  7 6 0) r el ati v e t o  e arli er ti m e  p oi nts. 
 
   T o  ass ess t h e  b o osti n g  of  v a c ci n e-i n d u c e d  n e utr ali zi n g 
a nti b o d y r es p o ns es  b y  a  b o ost er  d os e  of  P X V X [ADDRESS_1089732] or at or y 
   T o  o bt ai n  hi g h-tit er s er u m t o s u p p ort  n o n- cli ni c al st u di es 
(i n cl u di n g  p assi v e tr a nsf er st u di es)  b y  usi n g pl as m a p h er esis 
at  D a y  [ADDRESS_1089733] as m a fr o m s u bj e cts i m m u ni z e d  wit h 
o n e  d os e  a n d r e gi m e n fr o m  Gr o u p  9  s u bj e cts.  
   T o  o bt ai n  hi g h-tit er s er u m t o s u p p ort  n o n- cli ni c al st u di es 
(i n cl u di n g  p assi v e tr a nsf er st u di es)  b y  usi n g pl as m a p h er esis at  D a y  [ADDRESS_1089734] as m a fr o m  Gr o u p  1 0 s u bj e cts 
i m m u ni z e d  wit h  a  4 0/ 3 0 0  m c g si n gl e  a dj u v a nt  d os e. 
   T o f urt h er  ass ess  a nti -C HI K V  n e ut r ali zi n g  a nti b o d y, 
i n cl u di n g is ot y p e(s)  a n d  e pit o p e s p e cifi cit y,  b y  usi n g 
l e u k a p h er esis  at  D a y  1 8 2 ( Gr o u p  9 s u bj e cts)  a n d fr o m 
P B M C s a m pl es  at  D a ys  1,  8,  1 5  a n d  2 2 ( Gr o u p  1 0  s u bj e cts). 
   T o  c h ar a ct eri z e t h e  a nti -C HI K V  c ell ul ar i m m u n e  r es p o ns e 
b y  c oll e cti n g  P B M Cs  at  D a ys  1,  [ADDRESS_1089735] o g el
® a dj u v a nt  as r e q uir e d 
C O N T R O L  Dil u e nt,  us e d  as  a pl a c e b o  c o ntr ol f or D a y   1 a n d/ or D a y   1 5 i nj e cti o ns i n  c ert ai n tr e at m e nt  gr o u ps. 
M O D E  O F A D MI NI S T R A TI O N  I ntr a m us c ul ar (I M) i nj e cti o n 
P RI M A R Y E N D P OI N T  T h e  g e o m etri c  m e a n tit er  of  a nti - C HI K V  n e utr ali zi n g  a nti b o d y d et er mi n e d  b y l u cif er as e -b as e d  ass a y  at  D a y  [ADDRESS_1089736]  4 2 0  h e alt h y  U S  a d ults 
I N C L U SI O N 
C RI T E RI A  1.   M al e  or  f e m al e 
2.   A g e  1 8 t o  4 5  y e ars  ol d (i n cl usi v e) 3.   Usi n g  a n  a c c e pt a bl e  m et h o d  of  c o ntr a c e pti o n (if f e m al e  of 
c hil d b e ari n g  p ot e nti al).  
4.   A bl e  a n d  willi n g t o  pr o vi d e i nf or m e d  c o ns e nt f or st u d y 
p arti ci p ati o n.  
E X C L U SI O N 
C RI T E RI A  •   C urr e nt  a c ut e f e bril e  ill n ess. 
•   Cli ni c all y si g nifi c a nt  c ar di a c, r es pir at or y,  or r h e u m at ol o gi c 
dis e as e, i n t h e  o pi [INVESTIGATOR_9384] o n  of t h e I n v esti g at or. 
•   Pr e g n a nt  or  br e ast -f e edi n g. •   L a b or at or y  e vi d e n c e  of i nf e cti o n  wit h  H e p atitis  B/ C  or  HI V.  
•   Hist or y  of  c hi k u n g u n y a  vir us i nf e cti o n. 
•   Tr a v el t o  a  W H O - d esi g n at e d  c hi k u n g u n y a-e n d e mi c  r e gi o n 
wit hi n  3 0  d a ys  pri or t o  D a y  1. 
•   Hist or y  of  all er gi c r e a cti o n t o  a n y  c o m p o n e nt  of  C HI K V -V L P 
v a c ci n e,  Dil u e nt,  or  Al h y dr o g el
®. 
•   I n a bilit y t o  dis c o nti n u e s yst e mi c i m m u n o m o d ul at or y  or 
i m m u n os u p pr essi v e  m e di c ati o ns  3 0  d a ys  pri or t o  D a y  1. 
•   R e c ei v e d  or  pl a ns t o r e c ei v e  a n y li c e ns e d  v a c ci n e f r o m  3 0  d a ys 
pri or t o  D a y  1 t hr o u g h  D a y  5 7. 
•   R e c ei v e d  or  pl a ns t o r e c ei v e  a n i n v esti g ati o n al  a g e nt fr o m  [ADDRESS_1089737] u d y  p arti ci p ati o n.  
•   A n y  ot h er  c o n diti o n t h at, i n t h e  o pi [INVESTIGATOR_9384] o n  of t h e I n v esti g at or, 
cr e at es  a n  u n a c c e pt a bl e ris k t o t h e  s u bj e ct. 
•   A n y  ot h er  c o n diti o n t h at, i n t h e  o pi [INVESTIGATOR_9384] o n  of t h e I n v esti g at or,  m a y 
i nt erf er e  wit h t h e  c o n d u ct  of t h e st u d y  or t h e  v ali dit y  of t h e 
d at a.  
P X V X -C V -3 1 7 -0 0 1  P r ot o c ol  V 4. 0  2 2 M a y 2 0 2 0  C O N FI D E N TI A L  
P a g e  6   of  7 8    •   A n y  ot h er  c o n diti o n t h at, i n t h e  o pi [INVESTIGATOR_9384] o n  of t h e I n v esti g at or, 
cr e at es  a n  u n a c c e pt a bl e s af et y ris k f or  a p h er esis ( Gr o u p  9  a n d 
1 0 s u bj e cts  o nl y). 
•   R estri ct e d  v e n o us  a c c ess t h at  w o ul d  pr e v e nt t h e  c oll e cti o n  of 
P B M Cs,  pl as m a,  a n d l y m p h o c yt es  n e c ess ar y f or  p arti ci p ati o n ( Gr o u p  9  a n d  1 0 s u bj e cts  o nl y). 
•   W ei g ht  <  1 1 0  p o u n ds ( Gr o u p  9  a n d  1 0 s u bj e cts  o nl y) 
S T U D Y  D E SI G N  T his is  a  P h as e  [ADDRESS_1089738] u d y  h as  a  s cr e e ni n g  p eri o d  of  3 0  d a ys,  a  tr e at m e nt  a n d 
o bs er v ati o n  p eri o d  fr o m D a y   1 t o D a y   5 7, a f oll o w- u p  p eri o d t hr o u g h D a y  3 6 5  f or  all  gr o u ps  a n d  a n  a d diti o n al  f oll o w -u p  p eri o d t hr o u g h D a y  7 6 0 f or  s o m e  gr o u ps.  All  s u bj e cts  will  b e  u n bli n d e d  aft er t h eir D a y  3 6 5  visit.  
•   S u bj e cts i n  Gr o u ps  2,  3,  5,  6,  a n d  [ADDRESS_1089739] u d y 
aft er t h e  D a y  3 6 5  visit.  
•   S u bj e cts i n  Gr o u ps  [ADDRESS_1089740]  d os e  at  D a y  5 4 7. 
•   S u bj e cts i n  Gr o u p  [ADDRESS_1089741]  d os e  of  4 0/ 3 0 0  m c g 
at  D a y  5 4 7  a n d  will  c o nti n u e f oll o w- u p t o  D a y  7 6 0. 
Tr e at m e nt  gr o u ps  ar e s h o w n i n  T a bl e  4.  Gr o u p  1 (t h e  “ R ef er e n c e Gr o u p ”) r e c ei v es  a  d os e  of  2 0  m c g  C HI K V- V L P ( u n a dj u v a nt e d). 
Gr o u ps  [ADDRESS_1089742] o g el
® 3 0 0  m c g.  Gr o u p  9 r e c ei v es 
C HI K V - V L P  d os e:  2 0/ 3 0 0  m c g  a n d  Gr o u p  1 0 r e c ei v es  C HI K V- 
V L P  d os e:  4 0/ 3 0 0  m c g. 
Gr o u ps  1 t hr o u g h  8 r e c ei v e i nj e cti o ns  at  D a ys  1,  1 5,  a n d  2 9.  Gr o u ps 
1 t hr o u g h  4 r e c ei v e  P X V X 0 3 1 7  at  D a ys  1  a n d   2 9 ( pl a c e b o   at   D a y 
1 5);    Gr o u ps  5  t hr o u g h  7   r e c ei v e  P X V X 0 3 1 7  at    D a ys  1 5  a n d  2 9 ( pl a c e b o at  D a y  1);  a n d   Gr o u p  8 r e c ei v es P X V X 0 3 1 7   o nl y at  D a y   2 9 
( pl a c e b o  at  D a ys  1  a n d  1 5).  Gr o u p  [ADDRESS_1089743] as m a p h er esis  c oll e cti o n  at  D a y  5 7 ( m a n d at or y)  a n d  m a y  p arti ci p at e i n l e u k a p h er esis  c oll e cti o n  at  D a y 1 8 2  ( o pti o n al).   Gr o u p  [ADDRESS_1089744] as m a p h er esis  c oll e cti o n  at  D a y  2 2  ( m a n d at or y). 
P X V X -C V -3 1 7 -0 0 1  P r ot o c ol  V 4. 0  2 2 M a y 2 0 2 0  C O N FI D E N TI A L  
P a g e  7   of  7 8    D et ails  of  visits,  visit  wi n d o ws,  a n d  pr o c e d ur es  ar e  pr o vi d e d i n t h e 
S c h e d ul e  of  E v e nts f or  Gr o u ps  2,  3,  5,  6,  a n d  7 ( A p p e n di x  A 1 ), f or Gr o u ps  1,  4,  a n d  8  ( A p p e n di x  A 2), f or  Gr o u p  9 (A p p e n di x  B 1 )  a n d 
Gr o u p  1 0 ( A p p e n di x  B 2 ).  Aft er  si g ni n g t h e i nf or m e d  c o ns e nt f or m, 
s u bj e cts  will  u n d er g o s cr e e ni n g  pr o c e d ur es  u p t o  [ADDRESS_1089745] i nj e cti o n.  E x c e pt  f or t h e  o p e n-l a b el  Gr o u ps  9  a n d  1 0,  eli gi bl e s u bj e cts    will  b e  e nr oll e d  i nt o  a  tr e at m e nt  gr o u p  a c c or di n g  t o  a r a n d o mi z ati o n  s ch e d ul e  i n  a   1: 1: 1: 1: 1: 1: 1: [ADDRESS_1089746]  usi n g  a  m e m or y  ai d.  S u bj e cts  will  b e  s p e cifi c all y  as k e d t o 
r e c or d  l o c al  i nj e cti o n   sit e   e v e nts  ( p ai n,  r e d n ess,   s w elli n g)   a n d 
s yst e mi c e v e nts  ( or al t e m p er at ur e  ≥ 1 0 0. 4º F,  c hills,  m al ais e,  f ati g u e, 
h e a d a c h e,  m y al gi a,  j oi nt  p ai n,  a n d n a us e a).  A n y   ot h er a d v ers e  e v e nts 
a n d  m e di c ati o ns  us e d  t hr o u g h D a y   [ADDRESS_1089747] e d  at   D a y  1 ( b ef or e t h e first i nj e cti o n) a n d  D a ys   8,  1 5,  2 2,  2 9,  3 6, a n d   5 7 ( Gr o u p 
9  d o es  n ot  h a v e   a D a y   1 5  or D a y   2 2 visit  a n d  Gr o u p   1 0  d o es  n ot h a v e 
a  D a y  5 7  a n d  1 8 2  visit).  
A n  i nt eri m  st atisti c al  a n al ysis    will  b e  c arri e d  o ut  o n  s af et y  a n d 
i m m u n o g e ni cit y  d at a  t hr o u g h  t h e    D a y  5 7  visit.    Aft er  t h e  i nt eri m a n al ysis,  s u bj e cts  will  b e  e nr oll e d i n  Gr o u p  9  ( n  = 2 0).  S u bj e cts i n 
Gr o u p  [ADDRESS_1089748] u d y  p arti ci p ati o n  b ef or e  D a y  5 7  ( or  w h o 
d o   n ot   u n d er g o    D a y   [ADDRESS_1089749] as m a p h er esis  f or   ot h er  r e as o ns)   a n d s u bj e cts i n  Gr o u p  [ADDRESS_1089750] u d y p arti ci p ati o n  b ef or e  D a y 2 2  ( or w h o   d o  n ot  u n d er g o D a y   [ADDRESS_1089751] as m a p h er esis  f or  ot h er r e as o ns) m a y  b e  r e pl a c e d. 
F or   Gr o u ps  [ADDRESS_1089752] e d  at  D a ys  1 8 2  a n d  3 6 5.  All s u bj e cts  will  b e  u n bli n d e d aft er t h eir   D a y  3 6 5  visit;  s u bj e cts i n  Gr o u ps  2,  3,  5,  6,  a n d  [ADDRESS_1089753]  d os e  of  4 0/ 3 0 0 
m c g  at  D a y  5 4 7  a n d  will  c o nti n u e f oll o w -u p t o  D a y  7 6 0.  F oll o w - u p visits  a n d  bl o o d  c oll e cti o n f or s af et y  a n d i m m u n o g e ni cit y  will  b e 
P X V X -C V -3 1 7 -0 0 1  P r ot o c ol  V 4. 0  2 2 M a y 2 0 2 0  C O N FI D E N TI A L  
P a g e  8   of  7 8    p erf or m e d  at  D a ys  5 7 5 ( Gr o u p  4  o nl y)  a n d  [ADDRESS_1089754] u d y  a n d t h e i m m u n o g e ni cit y  a n d s af et y  d at a  h a v e  b e e n  l o c k e d. 
S E R O L O G Y  A nti b o d y  ( A b)  r es p o ns es t o  C HI K V -V L P  will  b e  d et er mi n e d  b y  a 
l u cif er as e-b as e d   a nti -C HI K V   n e utr ali z ati o n   ass a y.    Tit ers   ar e 
e x pr ess e d  as  t h e  r e ci pr o c al  of  t h e  s er u m  dil uti o n  a c hi e vi n g  8 0 % n e utr ali z ati o n ( N T 8 0). 
P ersist e n c e  of t h e i n d u c e d  r es p o ns e  will  b e  ass ess e d  b y  c o m p ari n g 
a nti -C HI K V  n e utr ali z ati o n r es p o ns es  at l at er ti m e  p oi nts  wit h t h os e o bt ai n e d  e arli er.  
A b  r es p o ns es   will  als o  b e  ass ess e d  b y  a  c o m m er ci al  a nti -C HI K V 
E LI S A  at  B as eli n e  a n d  D a y  5 7.  
V ari o us  P B M C  c o m p art m e nt  ( e. g.    m e m or y   B  a n d  h el p er   T  c ells)  
r es p o ns es  will  b e  ass ess e d  at s p e cifi c ti m e  p oi nts  d uri n g t h e st u d y. 
C RI T E RI A  F O R 
E V A L U A TI O N 
( E N D P OI N T S) I m m u n o g e ni cit y  E n d p oi nts  
A nti -C HI K V  n e utr ali z ati o n r es p o ns e  d at a f or  e a c h tr e at m e nt  gr o u p 
will  b e  e v al u at e d  a n d t a b ul at e d  a cr oss t h e  diff er e nt ti m e  p oi nts.  T h e pri m ar y  a n al ysis  will  b e  b as e d  o n  a nti -C HI K V  n e utr ali z ati o n tit ers m e as ur e d  at  [ADDRESS_1089755] i nj e cti o n ( D a y  5 7).  A n al ys es  will t h e n  b e  c o n d u ct e d  o n  i m m u n o g e ni cit y  d at a  c oll e ct e d  t hr o u g h   D a y 3 6 5 ( Gr o u ps  2,  3,  5,  6,  a n d  7)  or  D a y  7 6 0 ( Gr o u ps  1,  4,  a n d  8).  D at a 
fr o m  Gr o u p  [ADDRESS_1089756] e d  bri efl y  b el o w. 
G e o m etri c  M e a n  Tit er ( G M T)  a n d  G e o m etri c  M e a n  R ati o ( G M R) 
A nti -C HI K V   n e utr ali z ati o n   tit ers  will    b e  l o g arit h mi c all y 
tr a nsf or m e d   ( b as e 1 0).    T h e   G M Ts,    G M Rs   a n d   ass o ci at e d  9 5 % 
c o nfi d e n c e i nt er v als  f or  e a c h tr e at m e nt  gr o u p  will  b e  c o m p ut e d  b y 
e x p o n e nti ati n g  t h e  c orr es p o n di n g  l o g -tr a nsf or m e d  (l e ast  s q u ar es) m e a ns  a n d  9 5 %  c o nfi d e n c e li mits.  T h e  esti m at e  of t h e r a n d o m  err or us e d i n  c al c ul ati n g t h e  c o nf i d e n c e li mits  will  b e  o bt ai n e d fr o m  a n A N O V A   m o d el  wit h f a ct ors  of  tr e at m e nt   gr o u p   a n d st u d y sit e   as 
P X V X -C V -3 1 7 -0 0 1  P r ot o c ol  V 4. 0  2 2 M a y 2 0 2 0  C O N FI D E N TI A L  
P a g e  9   of  7 8    fi x e d  eff e cts.  C o m p aris o ns  of tr e at m e nt  gr o u ps  2 t hr o u g h  8 t o  gr o u p 
1  will  b e  d eri v e d fr o m  c o ntr asts  b as e d  o n t his  m o d el. 
Pr o p orti o n  ( p er c e nt a g e)  of s u bj e cts wit h   a nti-C HI K V  tit er e x c e e di n g 
d efi n e d  c ut -off  v al u es.  T h e  pr o p orti o n ( p er c e nt a g e)  of  s u bj e cts  wit h A b  r es p o ns es e x c e e di n g  sti p ul at e d c ut -off  v al u es  (f or e x a m pl e,  tit ers 
of  1 0  or  1 0 0), t o g et h er  wit h   a t w o-si d e d  9 5 % CI  b as e d   o n t h e Wils o n 
m et h o d,  will   b e t a b ul at e d f or e a c h  tr e at m e nt  gr o u p at  e a c h  ti m e  p oi nt. Fis h er’s  e x a ct  t ests    will  b e  p erf or m e d  t o  d eri v e  p -v al u es  f or  t h e p air wis e tr e at m e nt  gr o u p  c o m p aris o n s. 
Pr o p orti o n  ( p er c e nt a g e)  of s u bj e cts wit h   at l e ast  a f o ur-f ol d ris e o v er 
b as eli n e   i n   a nti -C HI K V   tit er.  T h e   pr o p orti o n   ( p er c e nt a g e)   of s u bj e cts  wit h  p ost -v a c ci n ati o n tit ers  at l e ast  f o ur ti m es  hi g h er t h a n pr e -v a c ci n ati o n,  t o g et h er    wit h  a  t w o -si d e d  9 5 %    CI  b as e d  o n  t h e 
Wils o n  m et h o d,  will  b e t a b ul at e d  f or  e a c h tr e at m e nt  gr o u p  at  e a c h 
ti m e  p oi nt.  Fis h er’s  e x a ct t ests  will  b e  p erf or m e d t o  d eri v e  p-v al u es f or t h e  p air wis e tr e at m e nt  gr o u p  c o m p aris o ns. 
S af et y  E n d p oi nts  
S u bj e cts  w h o  r e c ei v e  a  st u d y i nj e cti o n  will  h a v e  d at a  c oll e ct e d  f or 
s af et y  a n al ysis.  T h e  s af et y  a n d t ol er a bilit y  of  e a c h tr e at m e nt  gr o u p will  b e  c o m p ar e d i n  a  d es cri pti v e f as hi o n.  T h e s af et y  o bj e cti v es  will b e  ass ess e d  b y  a n al ysis  of  all  l o c al  a n d  s yst e mi c  p ost -i nj e cti o n s oli cit e d  e v e nts  a n d  ot h er  a d v ers e  e v e nts  c oll e ct e d  d uri n g t h e  [ADDRESS_1089757] is si g nifi c a nt 
(t w o-si d e d  0. 0 5 si g nifi c a n c e l e v el),  a n d if t h e  p er c e nt a g e  of s u bj e cts 
P X V X -C V -3 1 7 -0 0 1  P r ot o c ol  V 4. 0  2 2 M a y 2 0 2 0  C O N FI D E N TI A L  
P a g e  1 0   of  7 8    i n t h e  gr o u p t h at m e et  t h e s p e cifi c r es p o ns e d efi niti o n  is  n o l ess t h a n 
7 5 %. 
F or   f or m ul ati o ns   t h at   a p p e ar   i n disti n g uis h a bl e,   s el e cti o n   of   a 
f or m ul ati o n  will  b e  b as e d  o n  a  c o m bi n e d  b o d y  of  e vi d e n c e  o bt ai n e d fr o m t h e  G M T  v al u es,  p er c e nt a g e  of r es p o n d ers,  s af et y  pr ofil es  a n d 
a d diti o n al s u m m ar y  v ari a bl es, if  d e e m e d  n e c ess ar y.  
S T A TI S TI C A L 
M E T H O D S  St atisti c al  H y p ot h es es  
P air -wi s e  c o m p aris o ns  b et w e e n  r el e v a nt  tr e at m e nt  gr o u ps    will  b e 
b as e d  o n  t h e  p er c e nt a g e  of  s u bj e cts    wit h  f o ur -f ol d  ris e  i n  a nti- C HI K V tit er  a n d  G M Ts  m e as ur e d  at  D a y  5 7. ( [ADDRESS_1089758] 
i nj e cti o n).  S p e cifi c all y,  w e  will  b e t esti n g t h e  n ull  h y p ot h es es: 
H
0:  Pi =  P j  vs.  H 1:  Pi  ≠  P j 
w h er e  P i  a n d  P j  d e n ot e  t h e  pr o p orti o n  of  s u bj e cts    wit h  f o ur -f ol d 
ris e f or  a n y t w o  of t h e tr e at m e nt  gr o u ps, a n d  H
0: µi =  µj vs.  H 1: µi ≠  µj 
w h er e  µ i a n d  µ j d e n ot e t h e  G M T  f or a n y  t w o  of t h e tr e at m e nt  gr o u ps. 
All t ests  will  b e  c arri e d  o ut  at  a t w o -si d e d si g nifi c a n c e l e v el  of  0. [ADDRESS_1089759] u d y  P o p ul ati o n  .............................................................................................  2 8 
3. 3. 1   I n cl usi o n Crit eri a  .............................................................................  2 8 3. 3. 2   E x cl usi o n  Crit e ri a ............................................................................  2 8 
4   S T U D Y  V A C CI N E  ...................................................................................................  3 0 
4. 1   I n v esti g ati o n al V a c ci n e  ( P X V X 0 3 1 7) ............................................................  [ADDRESS_1089760] u d y  V a c ci n e  Pr e p ar ati o n  ...............................................................  3 2 
P X V X -C V -3 1 7 -0 0 1  P r ot o c ol  V 4. 0  2 2 M a y 2 0 2 0  C O N FI D E N TI A L  
P a g e  1 3   of  7 8   4. 2   C o ntr ol  V a c ci n e  ( Dil u e nt) ...............................................................................  [ADDRESS_1089761] eti o n:  F or I n di vi d u al  S u bj e cts  ....................................................  [ADDRESS_1089762] eti o n:  O v er all  .............................................................................  [ADDRESS_1089763] u d y Visits  ...................................................................................  4 2 
6. 1. 1   S cr e e ni n g ( - 3 0  d a ys t o  D a y  1)  – All   gr o u ps ....................................  4 2 6. 1. 2   D a y  1  –  All   gr o u ps ...........................................................................  4 2 6. 1. 3   D a y  8 ( + 3  d a ys)  –  All   gr o u ps ...........................................................  4 3 6. 1. 4   D a y  1 5 ( ±  1  d a y)  –  Gr o u ps  1 t hr o u g h  8  o nl y  ...................................  4 3 6. 1. 5   D a y  1 5 ( ±  2  d a ys)  –  Gr o u p  1 0  o nl y  .................................................  4 4 
6. 1. 6   D a y  2 2 ( + 3  d a ys)  –  Gr o u ps  1 t hr o u g h  8  o nl y  ..................................  4 4 
6. 1. 7   D a y  2 2 ( +  5  d a y)  –  Gr o u p   1 0  o nl y ...................................................  4 4 6. 1. 8    D a y  2 9 ( ±  1  d a y)  –  Gr o u ps  1- 9  ........................................................  4 4 
P X V X -C V -3 1 7 -0 0 1  P r ot o c ol  V 4. 0  2 2 M a y 2 0 2 0  C O N FI D E N TI A L  
P a g e  1 4   of  7 8   6. 1. 9   D a y  2 9 (- 1/ + 5  d a ys)  –  Gr o u p  1 0  o nl y ( p h o n e  c all  f oll o w- u p) .........  4 5 
6. 1. 1 0   D a y  3 6 ( + 3  d a ys)  –  Gr o u ps  1- 9 ........................................................  4 5 6. 1. 1 1   D a y  5 7 ( ±  3  d a ys f or  Gr o u ps  1- 8)  a n d (- 1 4/ + 3  d a ys f or  Gr o u p  9) ...  4 5  6. 1. 1 2    D a y  1 8 2 ( ±  7  d a ys)  –  Gr o u ps  1- 9 .....................................................  4 6 6. 1. 1 3   D a y  3 6 5 ( ±  7  d a ys)  –  Gr o u ps  [ADDRESS_1089764]  Visit ( ±  7  d a ys)  –  Gr o u p  [ADDRESS_1089765] ( ±  7  d a ys)  –  Gr o u ps  1  a n d  8  o nl y  ..............  4 7 6. 1. 1 6   D a y  5 5 4,  p h o n e  visit ( +  3  d a ys)  –  Gr o u p  4  o nl y  ..............................  4 7 
6. 1. 1 7   D a y  5 7 5 ( ±  3  d a ys)  –  Gr o u ps  4  o nl y  ................................................  4 7 
6. 1. 1 8   D a y  7 6 0 (- 1 4/ + 9 0  d a ys)  –  Gr o u ps  1,  [ADDRESS_1089766]  C o nfi d e nti alit y  ...................................................................................  6 9 1 0. 6   C o m p e ns ati o n  f or I nj ur y .................................................................................  6 9 1 0. 7   Cli ni c altri als. g o v  .............................................................................................  6 9 
1 0. 8   P u bli c  Dis cl os ur e  a n d  P u bli c ati o n  P oli c y  .......................................................  6 9 
1 0. 9   A m e n d m e nts  ...................................................................................................  6 9 
A P P E N DI X  A 1:   S C H E D U L E  O F  E V E N T S ( G R O U P S  2,  3,  5,  6,  A N D   7) ...........  7 1 
P X V X -C V -3 1 7 -0 0 1  P r ot o c ol  V 4. 0  2 2 M a y 2 0 2 0  C O N FI D E N TI A L  
P a g e  1 6   of  7 8   A P P E N DI X  A 2:   S C H E D U L E  O F  E V E N T S ( G R O U P S  1,  4,  A N D   8) ...................  7 2 
A P P E N DI X   B 1:  S C H E D U L E  O F  E V E N T S ( G R O U P   9 O N L Y)  ..........................  7 4 A P P E N DI X   B 2:  S C H E D U L E  O F  E V E N T S ( G R O U P   1 0 O N L Y)  ........................  7 5 A P P E N DI X  C:   T O XI CI T Y  G R A DI N G  S C A L E  ...................................................  [ADDRESS_1089767] at es  
W H O   W orl d  H e alt h  Or g a ni z ati o n  
P X V X -C V -3 1 7 -0 0 1  P r ot o c ol  V 4. 0  2 2 M a y 2 0 2 0  C O N FI D E N TI A L  
P a g e  1 8   of  7 8   1   I N T R O D U C TI O N 
1 .1   B a c k g r o u n d 
C hi k u n g u n y a  vir us  ( C HI K V)  is  a n  art hr o p o d -b or n e  al p h a vir us  of  t h e  f a mil y  T o g a viri d a e .   T h e 
C HI K V  viri o n  c o nt ai ns  a  p ositi v e -s e ns e  si n gl e-str a n d   R N A  g e n o m e   wit h  a  l o n g  o p e n  r e a di n g fr a m e  c o di n g f or  C a psi d ( C)  a n d  E n v el o p e ( E 1,  E 2,  E 3  a n d  6 K)  str u ct ur al  pr ot ei ns, t o g et h er  wit h f o ur  n o n-str u ct ur al  pr ot ei ns.  Si n c e t h e  first  c as e  r e p orts  of   C HI K V i n  a  1 9 5 2 -1 9 5 3  o ut br e a k i n T a n z a ni a  (R oss  1 9 5 6 ), t his dis e as e  h as  b e e n   e n d e mi c i n Afri c a  a n d  p arts   of Asi a  wit h  tr a ns missi o n 
o c c urri n g t hr o u g h  A e d es  a e g y pti  a n d  m or e r e c e ntl y  vi a  A e d es  al b o pi [INVESTIGATOR_550362]  (P o w ers   2 0 0 7). 
B e gi n ni n g  i n  [ADDRESS_1089768] e d  ar e as i n t h e  A m eri c as  a n d l o c al tr a ns missi o n  w as i d e ntifi e d i n  Fl ori d a,  P u ert o  Ri c o,  a n d t h e  U. S.  Vir gi n Isl a n ds.  As  of  A pril  2 2,  2 0 1 6,  1 0 3  c o u ntri es  or t errit ori es  h a v e  d o c u m e nt e d  c as es of  C HI K V i nf e cti o n  e x cl u di n g t h os e  c o u ntri es  w h er e  o nl y i m p ort e d  c as es  h a v e  b e e n  d o c u m e nt e d (C D C   2 0 1 7).  Alt h o u g h  m os q uit o es ar e  t h e pri m ar y   m o d e  of tr a ns missi o n  of C HI K V,   bl o o d- b or n e tr a ns missi o n  vi a n e e dl e  sti c k is  p ossi bl e. M at er n al -f et al tr a ns missi o n h as  b e e n   d o c u m e nt e d  d uri n g 
pr e g n a n c y ( St a pl es  2 0 1 7 ). 
F oll o wi n g  a n i n c u b ati o n  p eri o d  of  [ADDRESS_1089769] ati o ns i n cl u d e  hi g h f e v er, 
r as h,  g astr oi nt esti n al  c o m pli c ati o ns,  h e a d a c h e,    m us cl e  p ai n,  n a us e a,  f ati g u e,   m y al gi a,  a n d  j oi nt 
p ai n ( B or g h eri ni  2 0 0 7 , T a u bit z  2 0 0 7 , Pi [CONTACT_59207] o u x  2 0 0 7 ).  T h e  m ost  cl assi c  s y m pt o m  of  c hi k u n g u n y a 
is  a  d e bilit ati n g  p ol y art hr al gi a  t h at  is  pr es e nt  i n  gr e at er  t h a n  9 0 %  of  c as es.   T his  a c ut e  p h as e r es ol v es  wit hi n s e v er al  w e e ks,  b ut j oi nt  p ai n  a n d  art hritis  m a y  p ersist f or  m o nt hs  or  y e ars i n  u p t o 1 0 %  of i nf e ct e d i n di vi d u als. 
Di a g n osis  of  C HI K V i nf e cti o n  c a n  b e  b as e d  o n  eit h er  s er ol o g y  or  pr es e n c e  of  vir us.  D uri n g t h e 
a c ut e  p h as e  of  dis e as e,  t h er e  ar e  g e n er all y  hi g h  l e v els  of  vir e mi a  a n d  r e v ers e  tr a ns cri pt as e - p ol y m er as e  c h ai n r e a cti o n ( R T -P C R)  or  c ult ur e  c a n fr e q u e ntl y  b e  us e d t o  d et e ct i nf e cti o n.  Vir al R N A  c a n  b e  d et e ct e d  b y  R T -P C R. I m m u n o gl o b uli n  M (I g M)  a nti b o di es  d e v el o p  wit hi n  [ADDRESS_1089770]  f or  s e v er al    m o nt hs.  I m m u n o gl o b uli n    G  (I g G)  a nti b o di es  t y pi c all y 
d e v el o p  aft er  t h e  o ns et,  p ersisti n g  f or   w e e ks  t o    m o nt hs  a n d  p er h a ps  l o n g er.  Pr ot e cti o n  a g ai nst s u bs e q u e nt i nf e cti o n h as  b e e n  s h o w n t o c orr el at e  wit h  t h e pr es e n c e   of  a nti-C HI K V   a nti b o di es t h at n e utr ali z e t h e  vir us  in  vitr o . (Y o o n  2 0 1 5 ) 
T h er e  ar e  c urr e ntl y  n o  a p pr o v e d  v a c ci n es t o  pr e v e nt  C HI K V i nf e cti o n  or  dis e as e. 
P X V X -C V -3 1 7 -0 0 1  P r ot o c ol  V 4. 0  2 2 M a y 2 0 2 0  C O N FI D E N TI A L  
P a g e  1 9   of  7 8   Fi g u r e  1:  C HI K V  Gl o b al  B u r d e n  as  of  A p ril  2 2,  2 0 1 6  ( C D C  2 0 1 7) 
 
1 .2   N a m e  a n d  D es c ri pti o n  of I n v esti g ati o n al  V a c ci n e  
P X V X 0 3 1 7 is t h e  S p o ns or’s r es e ar c h  n a m e f or  C hi k u n g u n y a  Vir us ( E 1,  E 2  a n d  c a psi d  Pr ot ei ns, 
H E K  2 9 3  c ells)    Vir us -Li k e  P arti cl e    V a c ci n e  ( C HI K V -V L P  v a c ci n e).   P X V X 0 3 1 7  is   a  fi el d - f or m ul at e d v a c ci n e  wit h  t hr e e  c o m p o n e nts: C HI K V -V L P,   Dil u e nt as  r e q uir e d f or e a c h   d os e l e v el, 
a n d   Al h y dr o g el
® f or t h e  a dj u v a nt e d f or m ul ati o ns. C HI K V -V L P  is  c o m pris e d  of t hr e e r e c o m bi n a nt 
C HI K V  str u ct ur al  pr ot ei ns  d eri v e d  fr o m   C HI K V  S e n e g al  str ai n  3 7 9 9 7:   C a psi d/ c or e  ( 3 5  k D a), 
E n v el o p e  1 ( E 1,  5 5  k D a),  a n d  E n v el o p e  2 ( E 2,  5 0  k D a) i n st eril e  a q u e o us  b uff er.  C HI K V -V L P is ess e nti all y  i d e nti c al t o t h e V R C -C H K V L P [ADDRESS_1089771] o g el is  a  2 %  ( w/ w)  a q u e o us  s us p e nsi o n  of 
al u mi n u m  h y dr o xi d e. 
P X V X [ADDRESS_1089772] u di es 
V R C -C H K V L P 0 5 9 - 0 0-V P  ( C H K V L P 0 5 9) 
A d mi nistr ati o n   of C H K V L P [ADDRESS_1089773] e d   m o n k e ys fr o m C HI K V  c h all e n g e  ( V R C “ St u d y N o.  2 ”). 
I nf usi o n  of s er u m fr o m C H K V L P [ADDRESS_1089774] e d  i m m u n e-d efi ci e nt  mi c e fr o m C HI K V  c h all e n g e  ( V R C  “ St u d y N o.  3 ”).  T h es e  st u di es  pr o vi d e d n o n cli ni c al  e vi d e n c e   of t h e i m m u n o g e ni cit y   a n d   pr ot e cti v e   effi c a c y   of    C H K V L P [ADDRESS_1089775] u d y   p erf or m e d  i n  c o m pli a n c e    wit h    G o o d    L a b or at or y   Pr a cti c es  ( G L P).    R a b bits r e c ei v e d f o ur  1 m L  i ntr a m us c ul ar (I M) i nj e cti o ns  of  a  n o mi n al  d os e  of  4 0 m c g   of C H K V L P 0 5 9   or Dil u e nt ( pl a c e b o)  o n  D a ys  1,  [ADDRESS_1089776] or e d  t h e  b e n efit  of  a dj u v a nt.   Tr e at m e nt 
gr o u ps  ar e  s h o w n i n T a bl e   1.    C 5 7 Bl/ 6  x B al b/ c  F 1   h y bri d mi c e  w er e  i m m u ni z e d at  D a ys   0 a n d  3 5 
wit h  P X V X 0 3 1 7 ( Gr o u ps  1 t o  6)  or  C H K V L P 0 5 9 ( Gr o u ps  1 1 t o  1 6).  V L P  d os es  w er e  0. 2,  2,  or 2 0    m c g  of   V L P   wit h  or   wit h o ut  2 5 0    m c g  of  al u m  ( Al h y dr o g el).   All  of  t h e  a b o v e  d os es   w er e pr e p ar e d  i m m e di at el y  b ef or e  d osi n g.    A d diti o n all y,  d os es  of  2 a n d   2 0 m c g   of P X V X 0 3 1 7  wit h  2 5 0 m c g   of al u m  w er e  pr e p ar e d   4  h o urs ( Gr o u ps  7 a n d   8)  or  2 4  h o urs ( Gr o u ps  9 a n d   1 0)  b ef or e  d osi n g. 
C o ntr ol  gr o u ps  r e c ei v e d   C HI K V   D N A  pl as mi d  ( Gr o u p  1 7),  al u m  ( Gr o u p  1 8),  or  n o  tr e at m e nt 
( Gr o u p  1 9).  T h er e  w er e  [ADDRESS_1089777] er e d i n  0. 1  m L t ot al  v ol u m e b y  t h e  i ntr a m us c ul ar  (I M)  r o ut e.  S er u m   w as  t a k e n  at   D a ys  1 4,  2 8,  a n d  5 6.   D a y  1 4  s er a   w er e p o ol e d  b y  gr o u p  a n d  D a y  2 8  a n d  5 6 s er a  w er e  a n al y z e d i n di vi d u all y. 
A nti -C HI K V -V L P  a nti b o di es w er e  m e as ur e d   b y E LI S A   of  p o ol e d s er a at  D a y   1 4 (T a bl e   1). E LI S A 
a nti b o d y  tit ers    w er e  c al c ul at e d  as  t h e  5 0 %  e n d p oi nt  r es p o ns e  of  t h e  dil uti o n  c ur v e  ( E C 5 0). 
A nti b o d y  r es p o ns es  t o   C HI K V -V L P  v a c ci n e    w er e  e vi d e nt  at    D a y  1 4.   R es p o ns es    w er e  si mil ar b et w e e n  P X V X 0 3 1 7  a n d  C H K V L P 0 5 9, i n cr e as e d  wit h i n cr e asi n g  V L P  d os e,  a n d i n cr e as e d  at  all d os es  wit h t h e  a d diti o n  of  al u m.  R es p o ns es t o t h e  P X V X 0 3 1 7  d os es  pr e p ar e d  4  or  2 4  h o urs  pri or t o  i m m u ni z ati o n    w er e  als o  si mil ar  t o  t h os e  t o  t h e  s a m e   d os es  i m m e di at el y   b ef or e   d osi n g. 
N e gli gi bl e  E C 5 0  v al u es  w er e  o bs er v e d i n  all  c o ntr ol  gr o u ps. 
C HI K V -s p e cifi c  n e utr ali zi n g  a nti b o di es  w er e  m e as ur e d  b y  C HI K V- L u c  n e utr ali z ati o n  ass a y  at 
D a ys  1 4,  2 8,  a n d  5 6.  N e utr ali z ati o n tit ers  w er e  c al c ul at e d  as t h e  m a xi m u m s er u m  dil uti o n t h at n e utr ali z es  8 0 %  of l u cif er as e  a cti vit y f oll o wi n g i nf e cti o n  of  V er o  c ells  b y  a r e c o m bi n a nt C HI K V -L u c  vir us ( N T 8 0).  G e o m etri c  m e a n tit ers ( G M Ts)  w er e  c al c ul at e d  b y  gr o u p. 
N e utr ali z ati o n  w as  d et e ct e d i n  all  gr o u ps tr e at e d  wit h  V L P  at  D a y  [ADDRESS_1089778] u di es  
 
1. 2. 2. 1   V R C   3 1 1 
T h e  s af et y  a n d  i m m u n o g e ni cit y  of    C H K V L P 0 5 9    w er e  e v al u at e d  u n d er      B B -I N D    1 4 9 0 7    i n  
V R C  3 1 1,  a   P h as e  1  o p e n -l a b el,  d os e-es c al ati o n  tri al.  ( C h a n g  2 0 1 4 ,  w w w. cli ni c altri als. g o v : N C T 0 1 4 8 9 3 5 8).  H e alt h y  a d ult  p arti ci p a nts  1 8 t o  5 0  y e ars  ol d  w er e  assi g n e d t o  s e q u e nti al  d os e l e v el  gr o u ps t o r e c ei v e I M i nj e cti o ns  of  1 0 m c g,   2 0 m c g,   or  4 0 m c g  ( u n a dj u v a nt e d)  o n w e e ks   0,  4, a n d  [ADDRESS_1089779] -h o c  a n al ysis  of  n e utr ali zi n g  a nti b o d y  ( N a b)  b y l u cif er as e-b as e d  ass a y  w as  als o  p erf or m e d  b y  E m er g e nt  Tr a v el  H e alt h.  
All  i nj e cti o ns   w er e   w ell  t ol er at e d,   wit h  n o  s eri o us  a d v ers e  e v e nts  r e p ort e d.   T h e   m os t  c o m m o n 
l o c al r e a cti o n w as  mil d  i nj e cti o n sit e p ai n  ( 3 6 %) a n d  t h e  m ost  c o m m o n s yst e mi c r e a cti o n w as  mil d m al ais e ( 2 4 %).  N o  m o d er at e  or s e v er e r e a ct o g e ni cit y  w as   o bs er v e d. 
N e utr ali zi n g  a nti b o di es    w er e  d et e ct e d  i n  all  d os e  gr o u ps  aft er  t h e  s e c o n d  v a c ci n ati o n.    T h e 
g e o m etri c  m e a n  tit er ( G M T)  of t h e h alf  m a xi m u m  i n hi bit or y c o n c e ntr ati o n  (I C 5 0) w as   [ADDRESS_1089780] o c c urr e d  aft er t h e t hir d  v a c ci n ati o n i n  all  d os e  gr o u ps  ( 1 0  m c g  gr o u p  p = 0· 0 1 9 7,  2 0  m c g  gr o u p p < 0· 0 0 0 1,  a n d  4 0  m c g  gr o u p  p < 0· 0 0 0 1).  F o ur  w e e ks  aft er t h e t hir d  v a c ci n ati o n, t h e  G M T  of t h e I C 5 0  w as  8 7 4 5 f or t h e  1 0  m c g  gr o u p,  4 5 2 5 f or t h e  2 0  m c g  gr o u p,  a n d  5 3 9 0 f or t h e  4 0  m c g  gr o u p. 
T h es e fi n di n gs  w er e  c o nfir m e d  b y t h e  E m er g e nt  Tr a v el  H e alt h l u cif er as e -b as e d  ass a y t o  b e  us e d 
f or t h e P X V X -C V - 3 1 7- 0 0 1 tri al, d e m o nstr ati n g t h e  s uit a bilit y  of t h e E m er g e nt  Tr a v el  H e alt h  ass a y [ E m er g e nt  Tr a v el  H e alt h,  d at a  o n fil e]. 
 
1. 2. 2. [ADDRESS_1089781] o g e ni cit y 
s y m pt o m  w as  p ai n/t e n d er n ess  at t h e i nj e cti o n sit e r e p ort e d  as  mil d  b y  7 7  of  3 9 5 ( 1 9. 5 %) s u bj e cts 
w h o  r e c ei v e d  at l e ast  o n e  st u d y i nj e cti o n  a n d  as  m o d er at e  b y  3/ 3 9 5  s u bj e cts  ( 0. 8 %).  T h e  m ost 
fr e q u e ntl y r e p ort e d  s yst e mi c r e a ct o g e ni cit y  s y m pt o ms  w er e  mil d  or  m o d er at e  h e a d a c h e r e p ort e d 
b y  1 1 2  of  3 9 5  ( 2 8. 4 %)  s u bj e cts,    m al ais e  ( 1 0 1/ 3 9 5,  2 5. 6 %),  a n d    m y al gi a  ( 8 2/ 3 9 5,  2 0. 8 %).   N o r el at e d S A Es   h a v e o c c urr e d  a n d   n o cli ni c all y  si g nifi c a nt  p att er ns  of l a b or at or y a b n or m aliti es   h a v e b e e n  i d e ntifi e d. 
P X V X -C V -[ADDRESS_1089782]  i n d u cti o n  of  n e utr ali zi n g  a nti b o di es  4    w e e ks  aft er  t h e  s e c o n d  d os e  of ( bli n d e d) st u d y  v a c ci n e,  c o nsist e nt  wit h t h e  1: [ADDRESS_1089783] er,  hi g h er,  a n d/ or 
m or e  d ur a bl e i m m u n e r es p o ns es t h a n t h os e  a c hi e v e d i n  V R C  3 1 1  a n d  V R C  7 0 4.  S p e cifi c all y, f or d ur a bilit y,  t h e  i m m u n e  r es p o ns e  i n  t h e   4 0/ 3 0 0    m c g   gr o u p  (t h e  fi n al  s el e ct e d   d os e  f or  t h e P X V X 0 3 1 7  d e v el o p m e nt  pr o gr a m)  will  b e  ass ess e d t hr o u g h  1 0 4  w e e ks  ( 2  y e ars)  of  f oll o w - u p, c o m p ar e d  wit h  a  m a xi m u m  of  7 8  w e e ks ( 1 8  m o nt hs) i n  V R C [ADDRESS_1089784] a nti all y   e x p a n d  t h e   c o m bi n e d   s af et y   d at a b as e   of    C HI K V -V L P 
( P X V X 0 3 1 7 a n d  C H K V L P 0 5 9 V P)  r e ci pi e nts, wit h  all  s u bj e cts  pl a n n e d t o r e c ei v e at  l e ast  o n e  d os e of  P X V X 0 3 1 7. 
A n   o p e n  l a b el   gr o u p   gi v e n  a    C HI K V -V L P   d os e   of   2 0/ 3 0 0    m c g  ( Gr o u p   9,   n = 2 0)    will   b e 
i m pl e m e nt e d  t o  all o w  e v al u ati o n  of  c ell ul ar  i m m u n e  r es p o ns es  a n d  t o  pr o vi d e  a nti-C HI K V 
a nti b o di es  f or  us e  i n  st u di es  i n  a ni m als.  P eri p h er al  bl o o d    m o n o n u cl e ar  c ells  ( P B M Cs)   will  b e 
c oll e ct e d  at  s p e cifi c ti m e  p oi nts list e d i n  S e cti o n  2. [ADDRESS_1089785] u di es.  
A n  o p e n  l a b el  gr o u p  gi v e n  a    C HI K V -V L P  d os e  of  4 0/ 3 0 0    m c g  ( Gr o u p  1 0,  n = 1 0)    will  b e 
i m pl e m e nt e d  t o  all o w  e v al u ati o n  of  c ell ul ar  i m m u n e  r es p o ns es  a n d  t o  pr o vi d e  a nti-C HI K V a nti b o di es  f or  us e  i n  st u di es  i n  a ni m als.  P eri p h er al  bl o o d    m o n o n u cl e ar  c ells  ( P B M Cs)   wi ll  b e c oll e ct e d  at  s p e cifi c ti m e  p oi nts list e d i n  S e cti o n  2. [ADDRESS_1089786] o g el  d os e  of  3 0 0  m c g is  wit hi n t h e  r a n g e  of  d os es  of  al u m  a dj u v a nts  us e d i n  m a n y 
li c e ns e d  v a c ci n es, i n cl u di n g  E n g eri x- B
®.  T his  d os e  als o  cr e at es  a  c o n c e ntr ati o n r ati o t o  C HI K V- 
V L P  t h at a c hi e v es   hi g h ( ~ 9 0 %) l e v els  of  a ds or pti o n, t h o u g ht t o  e n h a n c e  b ot h i m m u n o g e ni cit y  a n d 
s h ort-t er m st a bilit y. 
T h e r o ut e  of  a d mi nistr ati o n (i ntr a m us c ul ar  – I M) is  c o nsist e nt  wit h t h at i n  V R C  3 1 1  a n d  V R C  7 0 4. 
 
Gr o u p  9  will r e c ei v e  a  d os e  of  2 0/ [ADDRESS_1089787]  s er o c o n v ersi o n r at es ( at D a ys  2 9  a n d  5 7),  G M T l e v els,  a n d s af et y- r el at e d  e v e nts. 
Gr o u p  1 0  will  r e c ei v e  a  si n gl e  d os e  of  4 0/ [ADDRESS_1089788]  d os e f or  Gr o u p  4 will   b e  4 0/ 3 0 0 m c g  ( b as e d  o n t h e fi n al s el e ct e d  d os e f or t h e P X V X 0 3 1 7 
d e v el o p m e nt  pr o gr a m).  
P X V X -C V -3 1 7 -0 0 1  P r ot o c ol  V 4. 0  2 2 M a y 2 0 2 0  C O N FI D E N TI A L  
P a g e  2 5   of  7 8  s 2   O B J E C TI V E S  A N D  E N D P OI N T S  
2 .1   P ri m a r y  O bj e cti v es  
T h e  pri m ar y  s af et y  o bj e cti v e is t o  e v al u at e t h e  s af et y  a n d t ol er a bilit y  of  8  f or m ul ati o n/s c h e d ul e 
c o m bi n ati o ns  of  P X V X [ADDRESS_1089789]  o n e  or  m or e f or m ul ati o n(s) f or  f urt h er v a c ci n e  d e v el o p m e nt.  S af et y  will  b e  ass ess e d  b y  m e as uri n g t h e i n ci d e n c e  of l o c al  a n d  s yst e mi c s oli cit e d  a d v ers e  e v e nts,  u ns oli cit e d  a d v ers e  e v e nts,  a n d s eri o us  a d v ers e  e v e nts.  
T h e  pri m ar y  i m m u n o g e ni cit y  o bj e cti v e  is  t o  ass ess  t h e  i n d u cti o n  of  a nti -C HI K V  n e utr ali zi n g 
a nti b o d y r es p o ns es  b y  diff er e nt f or m ul ati o ns  a n d  s c h e d ul es,  as  m e as ur e d  at  [ADDRESS_1089790] i nj e cti o n ( D a y  5 7). 
2 .2   S e c o n d a r y  O bj e cti v es  
T h e s e c o n d ar y i m m u n o g e ni cit y  o bj e cti v es i n cl u d e t h e f oll o wi n g: 
•  T o  ass ess t h e  ki n eti cs  of i n d u cti o n  of  a nti- C HI K V  n e utr ali zi n g  a nti b o d y r es p o ns es  b y 
diff er e nt f or m ul ati o ns  a n d s c h e d ul es,  as  m e as ur e d fr o m  [ADDRESS_1089791] i nj e cti o n 
( D a y  8) t o  [ADDRESS_1089792] i nj e cti o n ( D a y  5 7). 
•  T o  ass ess t h e  diff er e n c e i n  p ersist e n c e  of  n e utr ali zi n g  a nti b o d y r es p o ns es i n d u c e d  b y 
diff er e nt f or m ul ati o ns  a n d s c h e d ul es,  as  m e as ur e d  u p t o  [ADDRESS_1089793] i nj e cti o n 
( D a y  7 6 0) r el ati v e t o  e arli er ti m e  p oi nts. 
•  T o  ass ess t h e  b o osti n g  of  v a c ci n e-i n d u c e d  n e utr ali zi n g  a nti b o d y r es p o ns es  b y  a n 
a d diti o n al  d os e  of  P X V X [ADDRESS_1089794] or at or y i m m u n o g e ni cit y  o bj e cti v es i n cl u d e t h e f oll o wi n g: 
   T o  o bt ai n  hi g h-tit er s er u m t o s u p p ort  n o n- cli ni c al st u di es (i n cl u di n g  p assi v e tr a nsf er 
st u di es)  b y  usi n g  pl as m a p h er esis  at  D a y  [ADDRESS_1089795] as m a fr o m s u bj e cts i m m u ni z e d 
wit h  o n e  d os e  a n d r e gi m e n fr o m  Gr o u p  9 s u bj e cts. 
   T o  o bt ai n  hi g h-tit er s er u m t o s u p p ort  n o n- cli ni c al st u di es (i n cl u di n g  p assi v e tr a nsf er 
st u di es)  b y  usi n g  pl as m a p h er esis  at  D a y  [ADDRESS_1089796] as m a fr o m  Gr o u p  1 0 s u bj e cts 
i m m u ni z e d  wit h  4 0/ 3 0 0  m c g si n gl e  a dj u v a nt  d os e. 
   T o f urt h er  ass ess  a nti -C HI K V  n e utr a li zi n g  a nti b o d y, i n cl u di n g is ot y p e(s)  a n d  e pit o p e 
s p e cifi cit y,  b y  usi n g l e u k a p h er esis  at  D a y  1 8 2 ( Gr o u p  9 s u bj e cts)  a n d fr o m  P B M C 
s a m pl es  at  D a ys  1,  8,  1 5  a n d  2 2 ( Gr o u p  1 0 s u bj e cts). 
P X V X -C V -3 1 7 -0 0 1  P r ot o c ol  V 4. 0  2 2 M a y 2 0 2 0  C O N FI D E N TI A L  
P a g e  2 6   of  7 8  s    T o  c h ar a ct eri z e t h e  a nti -C HI K V  c ell ul ar i m m u n e r es p o ns e  b y  c oll e cti n g  P B M Cs  at D a ys 
1,  [ADDRESS_1089797] u d y c o nsists  of a  3 0-d a y  s cr e e ni n g  p eri o d, a tr e at m e nt a n d  o bs er v ati o n  p eri o d 
fr o m  D a y  1 t hr o u g h  D a y  5 7  a n d: 
•   F or  Gr o u ps  2,  3,  5,  6,  a n d  7:  a f oll o w- u p  p eri o d t hr o u g h  D a y  3 6 5. 
•   F or   Gr o u ps  1 a n d   8:  a f oll o w- u p  p eri o d t hr o u g h D a y   [ADDRESS_1089798]  d os e at 
D a y   5 4 7. 
•   F or  G r o u p  4:  a f oll o w- u p  p eri o d t hr o u g h  D a y  [ADDRESS_1089799]  d os e  of  4 0/ 3 0 0 
m c g  at  D a y   5 4 7. 
•   F or  Gr o u p  9:  a f oll o w- u p  p eri o d t hr o u g h  D a y  [ADDRESS_1089800]  m e et  all  of t h e f oll o wi n g  crit eri a i n  or d er t o  b e  e nr oll e d:  
1.   M al e  or  f e m al e 
2.   A g e  1 8 t o  4 5  y e ars  ol d (i n cl usi v e) 
3.   Usi n g  a n  a c c e pt a bl e  m et h o d  of  c o ntr a c e pti o n (if f e m al e  of  c hil d b e ari n g  p ot e nti al).  
4.   A bl e  a n d  willi n g t o  pr o vi d e i nf or m e d  c o ns e nt f or st u d y  p arti ci p ati o n.  
 
3. 3. 2   E x cl usi o n  C rit e ri a  
S u bj e cts  w h o  m e et  a n y  of t h e f oll o wi n g  crit eri a  c a n n ot  b e  e nr oll e d: 
 
1.   C urr e nt  a c ut e f e bril e  ill n ess. 
2.   Cli ni c all y si g nifi c a nt  c ar di a c, r es pir at or y,  or r h e u m at ol o gi c  dis e as e, i n t h e  o pi [INVESTIGATOR_9384] o n  of t h e 
I n v esti g at or. 
3.   Pr e g n a nt  or  br e ast -f e e di n g. 
 
4.   L a b or at or y  e vi d e n c e  of i nf e cti o n  wit h  H e p atitis  B/ C  or  HI V.  
P X V X -C V -[ADDRESS_1089801] o g el®. 
8.   I n a bilit y t o  dis c o nti n u e s yst e mi c i m m u n o m o d ul at or y  or i m m u n os u p pr essi v e  m e di c ati o ns  [ADDRESS_1089802] u d y  or t h e  v ali dit y  of t h e d at a.  
1 3.   A n y  ot h er  c o n diti o n t h at, i n t h e  o pi [INVESTIGATOR_9384] o n  of t h e I n v esti g at or,  cr e at es  a n  u n a c c e pt a bl e  s af et y 
ris k f or  a p h er esis ( Gr o u p  9  a n d  1 0 s u bj e cts  o nl y) 
[ADDRESS_1089803] as m a a n d 
l y m p h o c yt es  n e c ess ar y f or  p arti ci p ati o n ( Gr o u p  9  a n d  1 0 s u bj e cts  o nl y). 
1 5.   W ei g ht  <  1 1 0  p o u n ds ( Gr o u p  9  a n d  1 0 s u bj e cts  o nl y) 
P X V X -C V -3 1 7 -0 0 1  P r ot o c ol  V 4. 0  2 2 M a y 2 0 2 0  C O N FI D E N TI A L  
P a g e  3 0   of  7 8   4   S T U D Y  V A C CI N E  
4 .1   I n v esti g ati o n al  V a c ci n e ( P X V X 0 3 1 7) 
P X V X 0 3 1 7 is t h e  S p o ns or’s r es e ar c h  n a m e f or  C hi k u n g u n y a  Vir us ( E 1,  E 2  a n d  c a psi d  Pr ot ei ns, 
H E K  2 9 3  c ells)    Vir us -Li k e  P arti cl e    V a c ci n e  ( C HI K V  V L P  v a c ci n e).  P X V X 0 3 1 7  is  a  fi el d - f or m ul at e d v a c ci n e  wit h  t hr e e  c o m p o n e nts: C HI K V -V L P,   Dil u e nt as  r e q uir e d f or e a c h   d os e l e v el, 
a n d    Al h y dr o g el
® 2 %  f or  a dj u v a nt e d  f or m ul ati o ns.    T h es e  t hr e e  c o m p o n e nts  ar e  c o m bi n e d  i n 
pr es p e cifi e d  v ol u m es t o  a c hi e v e t h e f or m ul ati o ns  a n d  d os es i n di c at e d i n t his  pr ot o c ol. 
4. 1. 1   C HI K V -V L P  
C HI K V -V L P  is  a  vir us -li k e  p arti cl e  ( V L P)  c o m pris e d  of  t hr e e  r e c o m bi n a nt   C HI K V  str u ct ur al 
pr ot ei ns  d eri v e d  fr o m C HI K V  S e n e g al  str ai n  3 7 9 9 7:  C a psi d/ c or e ( C,  3 5 k D a),   E n v el o p e  1 ( E 1,  5 5 k D a),  a n d  E n v el o p e  2 ( E 2,  5 0  k D a).  C HI K V -V L P is  pr o d u c e d  b y tr a nsi e nt tr a nsf e cti o n  of  h u m a n e m br y o ni c  ki d n e y ( H E K)  [ADDRESS_1089804] as mi d  e n c o di n g  C a psi d ( C)  a n d  E 3, 
E 2,  [ADDRESS_1089805] as mi d -e n c o d e d  pr ot ei ns,  V L Ps  s elf -ass e m bl e 
a n d  ar e r el e as e d i nt o t h e  c ell  c ult ur e  m e di u m  as  ~ [ADDRESS_1089806].  T h e 
pr o d u cti o n  pr o c ess  d o es  n ot  us e  a ni m al -d eri v e d  r a w    m at eri als  or  a nti bi oti cs.  Pr o c ess  r esi d u als 
(i n cl u di n g  h ost  c ell  a n d r e c o m bi n a nt  D N A,  h ost  c ell  pr ot ei n,  a n d  B e n z o n as e)  w er e  ass ess e d t o  b e at  a c c e pt a bl e l e v els.  All  e x ci pi e nts  ar e  g e n er all y r e g ar d e d  as s af e  ( G R A S). 
T h e  C HI K V -V L P  dr u g  pr o d u ct is  a st eril e  a q u e o us  b uff er e d s ol uti o n fill e d i nt o  [ADDRESS_1089807] or e d i n  a  q u alifi e d, t e m p er at ur e -c o ntr oll e d  fr e e z er  at  ≤  – 7 0 ° C.  T h e 
t e m p er at ur e   sh o ul d   b e    m o nit or e d   b y   c h e c ki n g   a n d   r e c or di n g   c urr e nt,    m a xi m u m/ mi ni m u m 
t e m p er at ur e r e a di n gs i nsi d e t h e  v a c ci n e st or a g e  u nit  o n c e  e a c h  w or ki n g  d a y. 
T h e  c o m p ositi o n  of t h e  C HI K V -V L P  dr u g  pr o d u ct ( L ot  N u m b er  1 -FI N -2 9 4 9) is  s h o w n i n  T a bl e  
[ADDRESS_1089808] or a g e  c o n diti o n f or t h e  a dj u v a nt is r o o m t e m p er at ur e  n ot t o  e x c e e d  3 0 ° C. 
A v oi d fr e e zi n g.  S e e t h e  P h ar m a c y  M a n u al f or  a d diti o n al i nf or m ati o n. 
4. 1. [ADDRESS_1089809] u d y v a c ci n e:  
1.   3/ 1 0  m L  B D  L o- D os e ™  U - 1 0 0 i ns uli n s yri n g e  wit h  2 9  G a u g e  x  1/ 2 ( B D  C at  #  3 2 4 7 0 2) 
2.   1  m L  B D  L u er - L o k ™  S yri n g e st eril e, si n gl e  us e  p ol y c ar b o n at e ( B D  C at  #  3 0 9 6 2 8) 3.   2 5  G a u g e  B D ™  N e e dl e  [ADDRESS_1089810] eril e ( B D  C at  #   3 0 5 1 2 5) 
4.   2 5  G a u g e  B D ™  N e e dl e  1  1/ [ADDRESS_1089811] eril e ( B D  C at  #  3 0 5 1 2 7) 
 
Pl as m a p h er esis  a n d l e u k a p h er esis  kits  will  b e s u p pli e d  b y t h e  C o m m u nit y  Bl o o d  C e nt er  of Gr e at er  K a ns as  Cit y.  
 
4. 1. 5   F o r m ul ati o ns  a n d  D os es  of  P X V X 0 3 1 7  
T h e  u n a dj u v a nt e d f or m ul ati o n  of  P X V X 0 3 1 7  c o nt ai ns  C HI K V -V L P  a n d  Dil u e nt.  T h e  o nl y  d os e 
of t his  f or m ul ati o n  us e d i n t his  pr ot o c ol is  2 0  m c g  ( u n a dj u v a nt e d).  T h e  Al h y dr o g el - a dj u v a nt e d f or m ul ati o ns  of  P X V X [ADDRESS_1089812] o g el  a dj u v a nt. 
F o ur  d os es  ar e  us e d i n t his  pr ot o c ol:  [ADDRESS_1089813] u d y  V a c ci n e  P r e p a r ati o n  
T o  p r e p a r e t h e  2 0  m c g ( u n a dj u v a nt e d)  d os e:  
1.   0. 8  m L  Dil u e nt is  a d d e d t o  o n e  vi al ( 0. 8  m L)  of  C HI K V- V L P,  w hi c h is  n o w t h e  D os e 
Vi al  a n d  c o nt ai ns  1. [ADDRESS_1089814] a w n fr o m t h e  D os e  Vi al i nt o  a s yri n g e. 
 
T o  p r e p a r e t h e  6  m c g /  3 0 0  m c g  d os e: 
1.   0. [ADDRESS_1089815] a w n  a n d  dis c ar d e d fr o m  a  Dil u e nt  vi al ( 1. 2  m L),  w hi c h is  n o w t h e  D os e 
Vi al  a n d  c o nt ai ns  1. 1  m L.  
2.   0. 2  m L  C HI K V- V L P is  a d d e d t o t h e  Dil u e nt  Vi al ( D os e  vi al),  w hi c h  n o w  c o nt ai ns  1. [ADDRESS_1089816] a w n fr o m t h e  D os e  Vi al i nt o  a s yri n g e. 
P X V X -C V -3 1 7 -0 0 1  P r ot o c ol  V 4. 0  2 2 M a y 2 0 2 0  C O N FI D E N TI A L  
P a g e  3 3   of  7 8   T o  p r e p a r e t h e  1 0  m c g /  3 0 0  m c g  d os e: 
1.   0. 4  m L  C HI K V- V L P is  a d d e d t o  a  Dil u e nt  vi al ( 1. 2  m L),  w hi c h is  n o w t h e  D os e  Vi al  a n d 
c o nt ai ns  1. [ADDRESS_1089817] a w n fr o m t h e  D os e  Vi al i nt o  a s yri n g e. 
 
T o  p r e p a r e t h e  2 0  m c g /  3 0 0  m c g  d os e: 
1.   0. 8  m L  Dil u e nt is  a d d e d t o  a  C HI K V- V L P  vi al ( 0. 8  m L),  w hi c h is  n o w t h e  D os e  Vi al  a n d 
c o nt ai ns  1. [ADDRESS_1089818] a w n fr o m t h e  D os e  Vi al i nt o  a s yri n g e. 
T o  p r e p a r e t h e  4 0  m c g /  3 0 0  m c g  d os e: 
1.   0. [ADDRESS_1089819]  C HI K V- V L P  vi al ( 0. 8  m L)  a n d  mi x e d  b y  s wirli n g 
( First  d os e vi al).  
2.   0. [ADDRESS_1089820] o g el is  a d d e d t o  a s e c o n d  C HI K V- V L P  vi a l ( 0. 8  m L)  a n d  mi x e d  b y 
s wirli n g ( S e c o n d  d os e vi al).  
3.   B ot h  vi als  ar e  h el d  at r o o m t e m p er at ur e f or  [ADDRESS_1089821] a w n fr o m t h e s e c o n d  d os e  vi al i nt o s yri n g e. 
4. 2   C o nt r ol  V a c ci n e  ( Dil u e nt) 
T h e  c o ntr ol  v a c ci n e f or t his  pr ot o c ol is t h e  Dil u e nt  c o m p o n e nt  of  P X V X 0 3 1 7. 
 
T o  p r e p a r e t h e  Dil u e nt  d os e:  
1.   0. [ADDRESS_1089822] si g n a n d  d at e  a n  I nstit uti o n al R e vi e w  B o ar d  (I R B)- a p pr o v e d  c o ns e nt f or m (I C F).  F or f urt h er  d et ails  o n i nf or m e d  c o ns e nt, r ef er t o  S e cti o n   [ADDRESS_1089823]  w h o  si g ns  a n I C F  will r e c ei v e  a  s e q u e nti al t hr e e  di git i d e ntifi c ati o n  n u m b er  u ni q u e 
t o t h e  sit e ( e. g.,  0 0 1,  0 0 2 …).  W h e n  s cr e e ni n g i nf or m ati o n is  e nt er e d i nt o t h e  E D C  a  s u bj e ct  will b e  assi g n e d  a  s u bj e ct i d e ntifi c ati o n  n u m b er  wit h t h e f oll o wi n g  f or m at:  C V [ADDRESS_1089824] e m.  
E a c h  sit e  will  m ai nt ai n  a  s cr e e ni n g  e nr oll m e n t l o g t o  r e c or d t h e  e nr oll m e nt  or t h e  r e as o n(s)  f or 
s cr e e n  f ail ur e f or all  s u bj e cts w h o  r e c ei v e a s u bj e ct i d e ntifi c ati o n  n u m b er. R e as o n  f or s cr e e n f ail ur e 
will  als o  b e  c a pt ur e d i n t h e  M e dri o  E D C  dis p ositi o n  e C R F.  
R e -s cr e e ni n g: 
S u bj e cts  w h o  m e et   e x cl usi o n crit eri o n   1 ( c urr e nt a c ut e  f e bril e ill n ess) at  t h e ti m e  of t h eir s c h e d ul e d 
e nr oll m e nt  m a y   b e r e-s cr e e n e d aft er  r es ol uti o n  of t h eir a c ut e  ill n ess. S u bj e cts  w h o  m e et   e x cl usi o n crit eri a  6 t hr o u g h  1 0 ( pr o hi bit e d tr a v el  or  m e di c ati o ns  wit hi n  3 0  d a ys  pri or t o  D a y  1)  m a y  b e r e - s cr e e n e d  aft er t h e  a p pr o pri at e  d ur ati o n  h as  p ass e d.  T h er e  m a y  b e  sit u ati o ns i n  w hi c h  a n  eli gi bl e 
s u bj e ct is  n ot a bl e  t o  b e r a n d o mi z e d a n d  tr e at e d wit hi n   [ADDRESS_1089825] e d fr o m  s u bj e cts  at t h e  S cr e e ni n g  Visit  a n d  c o nfir m e d 
at t h e  D a y  1  ( B as eli n e)  Visit  a n d  will i n cl u d e  ( b ut  n ot  b e li mit e d t o)  d e m o gr a p hi c i nf or m ati o n, 
c urr e nt  a n d  p ast  m e di c al  c o n diti o ns,  a n d  pri or  a n d  c o n c o mit a nt  m e di c ati o ns t a k e n  wit hi n  [ADDRESS_1089826] et e  p h ysi c al  e x a mi n ati o n  will  b e  p erf or m e d  o n s u bj e cts  d uri n g t h e  S cr e e ni n g  Visit. 
P X V X -C V -3 1 7 -0 0 1  P r ot o c ol  V 4. 0  2 2 M a y 2 0 2 0  C O N FI D E N TI A L  
P a g e  3 5   of  7 8   T h e  e x a mi n ati o n s h o ul d i n cl u d e: 
•  H ei g ht 
•  B o d y  w ei g ht 
•  Vit al  si g ns •  G e n er al  a p p e ar a n c e  •  E y es -e ars - n os e-t hr o at 
•  H e a d -n e c k  
•  L u n gs- c h est  
•  H e art  
•  A b d o m e n 
•  M us c ul os k el et al  
•  L y m p h  n o d es 
•  S ki n •  E xtr e miti es  
•  N e ur ol o gi c al 
 
A  p h ysi c al  e x a m  m a y  b e  p erf or m e d  o n s u bj e cts  at  a d diti o n al ti m e  p oi nts if i n di c at e d  b y  A E 
r e p orti n g. 
[ADDRESS_1089827] e d f or s er u m t esti n g f or  H B V,  H C V  a n d HI V.  
N e utr ali zi n g  a nti b o d y  will  b e  ass ess e d  b y  a l u cif er as e- b as e d  a nti -C HI K V  n e utr ali z ati o n  ass a y  at 
D a y  1 ( pr e- v a c ci n ati o n)  a n d  at l at er ti m e  p oi nts.  
A nti b o d y  will  als o  b e  ass ess e d  b y  a li c e ns e d  a nti -C HI K V  E LI S A  at  D a y  1 ( pr e -v a c ci n ati o n)  a n d 
D a y  [ADDRESS_1089828] as m a p h er esis   a n d l e u k a p h er esis pr o c e d ur es  ( Gr o u p  9  o nl y) a n d pri or t o  pl as m a p h er esis  pr o c e d ur e ( Gr o u p  1 0  o nl y).  T h e  s u bj e ct  m ust  h a v e  a  n e g ati v e  pr e g n a n c y t est  o n D a y   1, pri or  t o st u d y v a c ci n e  a d mi nistr ati o n,  as  w ell  as   pri or t o  u n d er g oi n g pl as m a p h er esis at  D a y  5 7  a n d l e u k a p h er esis  at  D a y  1 8 2 ( Gr o u p  9  o nl y)  a n d  pl as m a p h er esis  pr o c e d ur e  at  D a y  2 2 
( Gr o u ps  1 0  o nl y).   T h e  I n v esti g at or    m ust  r e p ort  a n y  pr e g n a n ci es  as  d es cri b e d  i n  S e cti o n  7. 7. [ADDRESS_1089829]  als o  us e  a n  a c c e pt a bl e  m et h o d  of  c o ntr a c e pti o n fr o m  pri or t o  D a y  1 t hr o u g h  D a y  3 6 5 f or  Gr o u ps  2,  3,  5,  6,  a n d  7;  pri or t o  D a y  [ADDRESS_1089830]  c o nfir m t h at  c o ntr a c e pti o n m et h o ds    w er e  i niti at e d  pri or  t o    D a y  1  ( e. g.  h or m o n al  c o ntr a c e pti o n)  t o  b e  c o nsi d er e d  f ull y eff e cti v e.  
[ADDRESS_1089831]  D a y  3 6 5  visit. 
N eit h er  s u bj e cts,  n or cli ni c al  sit e  p ers o n n el ( e x c e pt f or t h e  u n bli n d e d st aff), i n cl u di n g t h e  pri n ci p al I n v esti g at or,  n or  t h e   S p o ns or    will  k n o w  s u bj e cts’  i n di vi d u al  tr e at m e nt  assi g n m e nts  u ntil  all s u bj e cts  h a v e  c o m pl et e d  t h eir  p arti ci p ati o n  i n  t h e  st u d y  t hr o u g h  t h e  l ast   D a y  [ADDRESS_1089832] o y e d t o r e d u c e t h e ris k  of i n a d v ert e nt  u n bli n di n g: 
•  Us e  of  a st a n d ar di z e d s yri n g e  a n d i nj e cti o n  v ol u m e f or  all  i nj e cti o ns. 
•  All f or m ul ati o ns  of  P X V X [ADDRESS_1089833] a c e b o  ar e i d e nti c al i n  a p p e ar a n c e.  
•  N o  S p o ns or  p ers o n n el  ot h er t h a n t h e  d esi g n at e d i n d e p e n d e nt  u n bli n d e d  m o nit or(s)  a n d 
t hir d- p art y  bi ost atisti cs  a n d  pr o gr a m mi n g st aff  pr o d u ci n g t h e  D a y  [ADDRESS_1089834]  will  h a v e  a c c ess t o tr e at m e nt  as si g n m e nts. 
•  S h o ul d  a n y s u bj e ct  or  bli n d e d st aff  m e m b er  b e c o m e i n a d v ert e ntl y  u n bli n d e d, t h e 
I n v esti g at or  will  pr o m ptl y ( wit hi n  2 4  h o urs  of t h eir  a w ar e n ess  of t h e  err or)  dis cl os e t h e 
e v e nt t o t h e  M e di c al  M o nit or ( M M) i n  a  bli n d e d f as hi o n ( dis cl osi n g  o nl y s u bj e ct  n u m b er, 
n ot tr e at m e nt) s o t h at  c orr e cti v e  a cti o n  c a n  b e i niti at e d.  T h e  u n bli n di n g s e q u e n c e  of 
e v e nts  will  b e  d o c u m e nt e d  a n d r et ai n e d  as s o ur c e  d o c u m e nts.  A  pr ot o c ol  d e vi ati o n  will 
b e  e nt er e d i n t h e  e C R F.  
 
Gr o u p  [ADDRESS_1089835] r ati o n  
F or    Gr o u ps  1  t hr o u g h  8  o n    D a ys  1,  1 5,  a n d  2 9  ( a n d  5 4 7  f or    Gr o u p  4)  b ef or e  st u d y  v a c ci n e 
a d mi nistr ati o n,  t h e    m e di c al  hist or y,  i n cl u di n g  p h ysi c al  e x a m  (if  i n di c at e d  b y  u p d at e d    m e di c al hist or y)  a n d  vit al si g ns,  a n d  c o n c o mit a nt  m e di c ati o ns  will  b e  c oll e ct e d  a n d  u p d at e d i n t h e s u bj e ct 
fil e,  s er u m  s a m pl es  will  b e  c oll e ct e d,  a n d f e m al es  of  c hil d b e ari n g  p ot e nti al  m ust  h a v e  a  n e g ati v e 
uri n e  pr e g n a n c y t est.  T h es e  a cti viti es  will  o c c ur f or  Gr o u p  [ADDRESS_1089836] er e d  b y  i ntr a m us c ul ar  i nj e cti o n   wit h  a  S p o ns or -pr o vi d e d  1 m L  s yri n g e  a n d  2 5 
g a u g e  1 ”  ( or   1. 5 ”, at   t h e  I n v esti g at or’s  dis cr eti o n)  n e e dl e  as  d es cri b e d   a b o v e,  usi n g  u ni v ers al 
P X V X -C V -[ADDRESS_1089837] e mi c  e v e nts  of  or al t e m p er at ur e  ≥  1 0 0. 4 °  F,  c hills,  m al ais e, f ati g u e,  h e a d a c h e,  m y al gi a, j oi nt p ai n,  a n d  n a us e a.  
S u bj e cts  will  b e tr ai n e d t o  c o m pl et e  a  m e m or y  ai d t o  o bs er v e,  m e as ur e,  a n d r e c or d t h es e  s oli cit e d 
A Es.  T o  m e as ur e  or al  t e m p er at ur e,  a  di git al t h er m o m et er will   b e  pr o vi d e d t o t h e s u bj e ct t o m e as ur e t h eir t e m p er at ur e  e a c h  d a y  a n d  r e c or d t h e m i n  t h eir  m e m or y  ai d.  T o  r e c or d i nj e cti o n  sit e l o c al r e a cti o n,  a r ul er will   b e  pr o vi d e d t o t h e s u bj e ct t o m e as ur e  t h e di a m et er   of r e d n ess a n d  s w elli n g at 
t h e l ar g est  p oi nt  of t h e r e a cti o n  e a c h  d a y  a n d r e c or d t h e m i n t h eir  m e m or y  ai d. 
St u d y  st aff  will r e vi e w t h e  si g ns  a n d  s y m pt o ms r e c or d e d  o n t h e  m e m or y  ai d  a n d t h e  a cti o n t a k e n 
f or t h e  e v e nt.  T h e  m e m or y  ai d  will  b e  c oll e ct e d  as  a  s o ur c e  d o c u m e nt. T h e I n v esti g at or  will t h e n ass ess  all  s oli cit e d  e v e nts  f or  s e v erit y  a n d  r el at e d n ess.  S e v erit y  will  b e  gr a d e d  a c c or di n g t o t h e T o xi cit y    Gr a di n g   S c al e  ( A p p e n di x    C).    T h e  r es ults  of  t h e  I n v esti g at or’s  ass ess m e nt    will  b e r e c or d e d  as  a s e p ar at e s o ur c e  d o c u m e nt fr o m t h e  m e m or y  ai d  a n d  will  b e  e nt er e d  o n t h e s oli cit e d 
a d v ers e  e v e nt  e C R F.  
S y m pt o ms  c o nti n ui n g  b e y o n d t h e  s oli cit e d  A E  c oll e cti o n   p eri o d ( 7  d a ys f oll o wi n g e a c h  i nj e cti o n), 
will  b e  c oll e ct e d  a n d r e c or d e d  o n t h e  a d v ers e  e v e nt  e C R F.  
P X V X -C V -3 1 7 -0 0 1  P r ot o c ol  V 4. 0  2 2 M a y 2 0 2 0  C O N FI D E N TI A L  
P a g e  3 9   of  7 8   5 .12   U ns oli cit e d  A d v e rs e  E v e nts  
U ns oli cit e d  a d v ers e  e v e nts  ( a n y A Es   n ot list e d  o n t h e m e m or y  ai d)  will   b e c oll e ct e d  f or t his st u d y 
a n d  d et ails  o n  d efi niti o n,  e v al u ati o n, r e p orti n g  p eri o ds  a n d  d o c u m e nt ati o n  ar e  o utli n e d i n  S e cti o n  7 . 
5 .13   P ri o r  a n d  C o n c o mit a nt  M e di c ati o ns  
At t h e  s cr e e ni n g  visit, t h e  d et ails  of  pri or  a n d  c o n c o mit a nt  m e di c ati o ns (t hr o u g h  3 0  d a ys  pri or t o D a y   1) us a g e  will   b e c oll e ct e d.  Fr o m  D a y   1 t hr o u g h D a y   5 7 visit  (f or  Gr o u ps  1- 9), a n d  a g ai n  fr o m D a y   5 4 7 t hr o u g h D a y   5 7 5 visit  (f or  Gr o u p  4  o nl y), a n d  fr o m D a y   1 t hr o u g h D a y   2 9 visit  ( Gr o u p 
1 0) t h e  d et ails  of  all  c o n c o mit a nt  m e di c ati o ns i n cl u di n g t h os e  ass o ci at e d  wit h s oli cit e d  A Es  a n d 
u ns oli cit e d  A Es  will  b e  c oll e ct e d.  
C o n c o mit a nt  m e di c ati o ns  ass o ci at e d  wit h  a  S A E  will  b e  c oll e ct e d t hr o u g h t h e  e n d  of t h e st u d y. 
[ADDRESS_1089838] a n ni n g t o r e c ei v e: 
•  S yst e mi c i m m u n os u p pr ess a nt  or i m m u n o m o d ul at or y  m e di c ati o ns ( e. g. 
c h e m ot h er a p e uti cs,  or al  c orti c ost er oi ds) fr o m  3 0  d a ys  pri or t o  D a y  1 t hr o u g h  D a y  5 7  visit 
(f or  Gr o u ps  1- 9)  a n d fr o m  3 0  d a ys  pri or t o  D a y  5 4 7 t hr o u g h  D a y  5 7 5  visit (f or  Gr o u p  4 
o nl y)  a n d fr o m  3 0  d a ys  pri or t o  D a y  1 t hr o u g h  D a y  2 2  visit (f or  Gr o u p  1 0) . 
•  Li c e ns e d  v a c ci n es fr o m  3 0  d a ys  pri or t o  D a y  1 t hr o u g h  D a y  5 7  visit (f or  Gr o u ps  1- 9) a n d 
fr o m  3 0  d a ys  pri or t o  D a y  5 4 7 t hr o u g h  D a y  5 7 5  visit (f or  Gr o u p  4  o nl y)  a n d fr o m  3 0 
d a ys  pri or t o  D a y  1 t hr o u g h  D a y  2 2  visit (f or  Gr o u p  1 0). 
•  I n v esti g ati o n al  a g e nts fr o m  [ADDRESS_1089839] u d y 
p arti ci p ati o n.  
•  P arti ci p a nts  c a n n ot  u n d er g o  pl as m a p h er esis  or l e u k a p h er esis if t h e y  ar e  o n: 
o  A nti pl at el et  a g e nts,  Pl a vi x
® a n d/ or  Ti cli d® 
o  A nti c o a g ul a nts,  C o u m a di n,  Effi e nt®,  a n d/ or Brili nt a® 
 
 
T h e  hist or y  of  all  pr o hi bit e d  m e di c ati o ns  at  a n y ti m e  d uri n g st u d y  p arti ci p ati o n (r e g ar dl ess  of 
ass o ci ati o n  wit h  a n  A E)  will  b e  c oll e ct e d.  
[ADDRESS_1089840]  o nl y i n t h e  c as e  of  a 
m e di c al  e m er g e n c y  w h er e  k n o wl e d g e  of t h e tr e at m e nt is  n e c ess ar y f or t h e  m a n a g e m e nt  of  a n  
P X V X -C V -3 1 7 -0 0 1  P r ot o c ol  V 4. 0  2 2 M a y 2 0 2 0  C O N FI D E N TI A L  
P a g e  4 0   of  7 8   a d v ers e  e v e nt.   T h e  I n v esti g at or    will  n otif y  t h e    M e di c al    M o nit or  ( M M)  (i n  a  bli n d e d    m a n n er) 
i m m e di at el y  aft er  u n bli n di n g,  d o c u m e nt t h e  r e as o n  a n d  cir c u mst a n c es  f or t h e  u n bli n di n g  e v e nt, 
a n d  distri b ut e  u n bli n di n g i nf or m ati o n  o nl y  as  n e e d e d f or  m e di c al  m a n a g e m e nt.  
[ADDRESS_1089841]’s 
s o ur c e  d o c u m e nts  a n d  i n  t h e  s u bj e ct’s  pr ot o c ol  d e vi ati o n  e C R F.   T h e  S p o ns or    will  r e vi e w  all 
pr ot o c ol   d e vi ati o ns   o n   a n   o n g oi n g   b asis   a n d    will   b e  r es p o nsi bl e  f or   c at e g ori zi n g   pr ot o c ol d e vi ati o ns  as I m p ort a nt  Pr ot o c ol  D e vi ati o ns (I P Ds). I P Ds  m a y r e q uir e  a d diti o n al  d o c u m e nt ati o n as r e q u est e d  b y t h e  S p o ns or. 
[ADDRESS_1089842] eti o n:  F o r I n di vi d u al  S u bj e cts  
A n i n di vi d u al  s u bj e ct is  c o nsi d er e d t o  c o m pl et e  st u d y  p arti ci p ati o n  aft er  c o m pl eti o n  of t h e  D a y 
[ADDRESS_1089843] u d y 
p arti ci p ati o n  b ef or e t h e  D a y  7 6 0  visit (f or  Gr o u ps  1,  4,  a n d  8),  D a y  3 6 5 ( Gr o u ps  2,  3,  5,  6,  a n d  7) a n d  b ef or e t h e  D a y  1 8 2  visit (f or  Gr o u p  9)  a n d  b ef or e t h e  D a y  2 9  visit (f or  Gr o u p  1 0). 
A n  e nr oll e d s u bj e ct  m a y  v ol u nt aril y  wit h dr a w  c o ns e nt f or f urt h er  p arti ci p ati o n  at  a n y ti m e  b ef or e 
t h e  D a y  7 6 0  visit (f or  Gr o u ps  1,  4,  a n d  8),  D a y  3 6 5 ( Gr o u ps  2,  3,  5,  6,  a n d  7)  a n d  b ef or e t h e  D a y 
1 8 2  visit (f or  Gr o u p  9)  a n d  b ef or e t h e  D a y  2 9  visit (f or  Gr o u p  1 0).  T h e I n v esti g at or  will r e q u est 
( b ut  c a n n ot  r e q uir e)  s u c h  s u bj e cts  t o  pr o vi d e  t h e  r e as o n(s)  f or    wit h dr a w al  of  c o ns e nt  a n d  t o u n d er g o  a n  E arl y  Dis c o nti n u ati o n  visit. 
I n  a d diti o n,  t h e  I n v esti g at or,  at  his  or  h er  dis cr eti o n,    m a y    wit h dr a w  a  s u bj e ct  fr o m  f urt h er 
p arti ci p ati o n i n t h e st u d y.  Crit eri a f or  wit h dr a w al  b y t h e I n v esti g at or i n cl u d e: 
•  N o n c o m pli a n c e  wit h t h e  pr ot o c ol 
•  Pr e g n a n c y  
•  I m m e di at e  h y p ers e nsiti vit y r e a cti on  ass o ci at e d  wit h  a st u d y  i nj e cti o n •  L oss t o f oll o w- u p  – r e q uir es  d o c u m e nt ati o n  of  at l e ast  [ADDRESS_1089844]’s  pr oj e ct e d 
l ast visit.  
•  Gr a d e  [ADDRESS_1089845] u d y  i nj e cti o n. 
P X V X -C V -3 1 7 -0 0 1  P r ot o c ol  V 4. 0  2 2 M a y 2 0 2 0  C O N FI D E N TI A L  
P a g e  4 1   of  7 8   •  Ot h er r e as o n(s)  w hi c h, i n t h e  o pi [INVESTIGATOR_9384] o n  of t h e I n v esti g at or, i n di c at es t h at  c o nti n u e d 
p arti ci p ati o n i n t h e st u d y is  n ot i n t h e  b est i nt er est  of t h e  s u bj e ct. 
[ADDRESS_1089846] a c e d  at  t h e  S p o ns or’s  dis cr eti o n.  S u bj e cts    w h o  u n d er g o    E arl y    Dis c o nti n u ati o n  aft er  first v a c ci n e  a d mi nistr a ti o n  will  n ot  b e r e pl a c e d, f or  Gr o u ps  [ADDRESS_1089847] u d y  p arti ci p ati o n  b ef or e    D a y  5 7  ( or    w h o  d o  n ot  u n d er g o    D a y  [ADDRESS_1089848] as m a p h er esis  f or   ot h er  r e as o ns)    m a y   b e  r e pl a c e d   a n d    Gr o u p   [ADDRESS_1089849] u d y 
p a rti ci p ati o n  b ef or e D a y   2 2 ( or w h o   d o  n ot  u n d er g o D a y   [ADDRESS_1089850] as m a p h er esis  f or  ot h er r e as o ns) m a y 
b e  r e pl a c e d. 
[ADDRESS_1089851] eti o n:   O v e r all 
T h e  st u d y  is  pl a n n e d  t o  b e  c o m pl et e d  aft er  all  s u bj e cts  h a v e  c o m pl et e d  t h e   D a y  7 6 0  visit  (f or 
Gr o u ps  1,  4,  a n d  8  o nl y),  D a y  3 6 5  visit  (f or  Gr o u ps  2,  3,  5,  6  a n d  7)  a n d t h e  D a y  1 8 2  visit  f or Gr o u p  9  a n d  t h e D a y   2 9 visit  f or  Gr o u p  1 0 ( or E arl y  Dis c o nti n u ati o n,  as  a p pr o pri at e) , all  n e c ess ar y 
s af et y  f oll o w-u p  h as  b e e n  c o m pl et e d,  a n d  all  d at a  h as  b e e n  m o nit or e d  a n d  q u eri es  ar e  r es ol v e d. 
T h e  S p o ns or r es er v es t h e ri g ht t o t er mi n at e t h e st u d y  pri or t o t h e  pl a n n e d st u d y c o m pl eti o n. 
P X V X -C V -[ADDRESS_1089852] u d y  Visits  
6. 1. 1  S c r e e ni n g (- 3 0  d a ys t o  D a y  1)  –  All  g r o u ps 
T h e f oll o wi n g  will t a k e  pl a c e  d uri n g t h e  visit,  w hi c h  will  o c c ur  wit hi n  3 0  d a ys  pri or t o  D a y  1: 
•  I nf or m e d  c o ns e nt 
•  D e m o gr a p hi cs 
•  R e vi e w  of  eli gi bilit y  crit eri a  
•  M e di c al   hist or y 
•  P h ysi c al  e x a m  
•  Vit al  si g ns 
•  Bl o o d  C oll e cti o n  f or: 
o   H B V,  H C V,  HI V  e v al u ati o n  
•  Uri n e  pr e g n a n c y (f e m al es  of  c hil d b e ari n g  p ot e nti al)  
•  Pri or  a n d  c o n c o mit a nt  m e di c ati o ns  
 
6. 1. 2   D a y  1  –  All   g r o u ps 
T h e f oll o wi n g  will t a k e  pl a c e  d uri n g t h e  visit  a n d  pri or  t o st u d y  v a c ci n e  a d mi nistr ati o n: 
•  U p d at e d  m e di c al   hist or y 
•  C o nfir m ati o n I n cl usi o n/ E x cl usi o n  crit eri a  ar e  m et  
•  Dir e ct e d  p h ysi c al  e x a mi n ati o n, if i n di c at e d  b y  u p d at e d  m e di c al  hist or y 
•  Vit al  si g ns 
•  Bl o o d  C oll e cti o n ( pr e- d os e)  f or: 
o   A nti -C HI K V  n e utr ali z ati o n  
o   A nti - C HI K V  E LI S A ( o nl y f or  Gr o u ps  1- 9) 
o   P B M C  c oll e cti o n –  Gr o u p  9  a n d  1 0 s u bj e cts  o nl y 
•  Uri n e  pr e g n a n c y t est (f e m al es  of  c hil d b e ari n g  p ot e nti al)  
•  Pri or  a n d  c o n c o mit a nt  m e di c ati o ns  
•  R a n d o mi z ati o n/ E nr oll m e nt 
P X V X -C V -[ADDRESS_1089853] u d y  v a c ci n e  a d mi nistr ati o n: 
•  A c ut e  o bs er v ati o n f or  u p t o  3 0  mi n ut es  
•  Vit al si g ns  aft er  at l e ast  3 0  mi n ut es  a n d  n o l at er t h a n  6 0  mi n ut es  
•  A E (s oli cit e d  a n d  u ns oli cit e d)  a n d  S A E  e v al u ati o n  
•  C o n c o mit a nt  m e di c ati o ns  
•  M e m or y  ai d, r ul er  a n d t h er m o m et er  distri b uti o n  a n d  tr ai ni n g 
 
6. 1. 3   D a y  8 ( + 3  d a ys)  –  All   g r o u ps 
T h e f oll o wi n g  pr o c e d ur es  will t a k e  pl a c e  at t his  visit:  
•  R e vi e w  of t h e  m e m or y  ai d  
•  C o n c o mit a nt  m e di c ati o ns  
•  A E (s oli cit e d  a n d  u ns oli cit e d)  a n d  S A E  e v al u ati o n  
•  Bl o o d  c oll e cti o n f or  A nti- C HI K V  n e utr ali z ati o n  
•  P B M C  c oll e cti o n –  Gr o u p  1 0 s u bj e cts  o nl y 
 
6. 1. 4   D a y  1 5 ( ±  1  d a y)  –  G r o u ps  [ADDRESS_1089854] u d y  v a c ci n e  a d mi nistr ati o n: 
•  Uri n e  pr e g n a n c y t est (f e m al es  of  c hil d - b e ari n g p ot e nti al)  
•  C o nfir m ati o n  of  c o nti n u e d  eli gi bilit y  
•  Vit al  si g ns 
•  C o n c o mit a nt  m e di c ati o ns  
•  A E ( u ns oli cit e d)  a n d  S A E  e v al u ati o n  
•  Bl o o d  c oll e cti o n f or  a nti- C HI K V  n e utr ali z ati o n  
St u d y  V a c ci n e  A d mi nist r ati o n  
 
T h e f oll o wi n g  will t a k e  pl a c e  d uri n g t h e  visit  a n d  aft er  st u d y  v a c ci n e  a d mi nistr ati o n: 
•  A c ut e  o bs er v ati o n f or  u p t o  3 0  mi n ut es  
•  Vit al si g ns   aft er  at l e ast  3 0  mi n ut es  a n d  n o l at er t h a n  6 0 mi n ut es  
•  Iss ui n g  of  m e m or y ai d  
P X V X -C V -3 1 7 -0 0 1  P r ot o c ol  V 4. 0  2 2 M a y 2 0 2 0  C O N FI D E N TI A L  
P a g e  4 4   of  7 8    
6. 1. 5   D a y  1 5 ( ±  2  d a ys)  –  G r o u p  [ADDRESS_1089855] a c e  at t his  visit:  
•  C o n c o mit a nt  m e di c ati o ns  
•  A E ( u ns oli cit e d)  a n d  S A E  e v al u ati o n  
•  Bl o o d  c oll e cti o n f or  A nti- C HI K V  n e utr ali z ati o n  
•  P B M C  c oll e cti o n  
 
6. 1. 6   D a y  2 2 ( + 3  d a ys)  –  G r o u ps  [ADDRESS_1089856] a c e  at t his  visit:  
•  R e vi e w  of t h e  m e m or y  ai d  
•  C o n c o mit a nt  m e di c ati o ns  
•  A E (s oli cit e d  a n d  u ns oli cit e d)  a n d  S A E  e v al u ati o n  
•  Bl o o d  c oll e cti o n f or  A nti- C HI K V  n e utr ali z ati o n  
 
6. 1. 7   D a y  2 2 ( +  5  d a y)  –  G r o u p  [ADDRESS_1089857] a c e  d uri n g t h e  visit: 
•  Uri n e  pr e g n a n c y t est (f e m al es  of  c hil d - b e ari n g p ot e nti al)  
•  C o nfir m ati o n  of  c o nti n u e d  eli gi bilit y  
•  C o n c o mit a nt  m e di c ati o ns  
•  A E ( u ns oli cit e d)  a n d  S A E  e v al u ati o n  
•  Bl o o d  C oll e cti o n  f or: 
o   A nti -C H I K V n e utr ali z ati o n  
o   P B M C  c oll e cti o n  
o   Pl as m a p h er esis  pr o c e d ur e  p erf or m e d  at t h e  bl o o d  b a n k 
   A E f oll o w- u p  [ADDRESS_1089858] as m a p h er esis  
 
6. 1. 8   D a y  2 9 ( ±  1  d a y)  –  G r o u ps   1- [ADDRESS_1089859] a c e  d uri n g t h e  visit  a n d  pri or  t o  v a c ci n ati o n: 
•  Uri n e  pr e g n a n c y t est (f e m al es  of  c hil d - b e ari n g p ot e nti al)  
•  C o nfir m ati o n  of  c o nti n u e d  eli gi bilit y  
•  Vit al  si g ns 
P X V X -C V -3 1 7 -0 0 1  P r ot o c ol  V 4. 0  2 2 M a y 2 0 2 0  C O N FI D E N TI A L  
P a g e  4 5   of  7 8   •  C o n c o mit a nt  m e di c ati o ns  
•  A E ( u ns oli cit e d)  a n d  S A E  e v al u ati o n  
•  Bl o o d  C oll e cti o n  f or: 
o   A nti -C HI K V  n e utr ali z ati o n  
o   P B M C  c oll e cti o n  –  Gr o u p  [ADDRESS_1089860] u d y  v a c ci n e  a d mi nistr ati o n 
•  A c ut e  o bs er v ati o n f or  u p t o  3 0  mi n ut es  
•  Vit al si g ns  aft er  at l e ast  3 0  mi n ut es  a n d  n o l at er t h a n  6 0  mi n ut es  
•  Iss ui n g  of  m e m or y ai d  
 
6. 1. 9   D a y  2 9 (- 1/ + 5  d a ys)  –  G r o u p  1 0  o nl y ( p h o n e  c all f oll o w- u p)  
•  C o n c o mit a nt  m e di c ati o ns  •  A E ( u ns oli cit e d)  a n d  S A E  e v al u ati o n  
 
6. 1. 1 0   D a y  3 6 ( + 3  d a ys)  –  G r o u ps   1- [ADDRESS_1089861] a c e  at t his  visit:  
•  R e vi e w  of t h e  m e m or y  ai d  
•  C o n c o mit a nt  m e di c ati o ns  
•  A E (s oli cit e d  a n d  u ns oli cit e d)  a n d  S A E  e v al u ati o n  
•  Bl o o d  c oll e cti o n f or  a nti- C HI K V  n e utr ali z ati o n  
 
6. 1. 1 1   D a y  5 7 ( ±  3  d a ys f o r  G r o u ps  1- 8)  a n d (- 1 4/ + 3  d a ys f o r  G r o u p  9) 
T h e f oll o wi n g  pr o c e d ur es  will t a k e  pl a c e  at t his  visit:  
•  C o n c o mit a nt  m e di c ati o ns  
•  A E ( u ns oli cit e d)  a n d  S A E  e v al u ati o n  
•  Uri n e  pr e g n a n c y (f or f e m al es  of  c hil d b e ari n g  p ot e nti al i n  Gr o u p  9) 
•  C o nfir m ati o n  of  e x cl usi o n ar y  crit eri a ( Gr o u p  9  o nl y) 
•  Bl o o d  c oll e cti o n  f or: 
o   A nti -C HI K V  n e utr ali z ati o n  
o   A nti -C HI K V  E LI S A  
o   P B M C  c oll e cti o n –  Gr o u p  [ADDRESS_1089862] as m a p h er esis  pr o c e d ur e  p erf or m e d  at t h e  bl o o d  b a n k ( * Gr o u p  9 s u bj e cts  o nl y) 
P X V X -C V -3 1 7 -0 0 1  P r ot o c ol  V 4. 0  2 2 M a y 2 0 2 0  C O N FI D E N TI A L  
P a g e  4 6   of  7 8      * A E f oll o w- u p  [ADDRESS_1089863] as m a p h er esis  
 
6. 1. 1 2   D a y  1 8 2 ( ±  7  d a ys)  –  G r o u ps   1- [ADDRESS_1089864] a c e  at t his  visit:  
•  S A E  e v al u ati o n  
•  C o n c o mit a nt  m e di c ati o ns  p ot e nti all y r el at e d t o  S A Es  or  pr o hi bit e d  m e di c ati o ns  
•  Uri n e  pr e g n a n c y (f or f e m al es  of  c hil d b e ari n g  p ot e nti al i n  Gr o u p  9) 
•  C o nfir m ati o n  of  e x cl usi o n ar y  crit eri a ( Gr o u p  9  o nl y) 
•  Bl o o d  c oll e cti o n  f or: 
o   A nti -C HI K V  n e utr ali z ati o n  
o   P B M C  c oll e cti o n –  Gr o u p  9 s u bj e cts  o nl y 
o   L e u k a p h er esis  pr o c e d ur e  p erf or m e d  at t h e  bl o o d  b a n k ( o pti o n al  pr o c e d ur e f or 
* Gr o u p  9 s u bj e cts  o nl y) 
   * A E f oll o w- u p  [ADDRESS_1089865]  l e u k a p h er esis 
 
6. 1. 1 3   D a y  3 6 5 ( ±  7  d a ys)  –  G r o u ps  [ADDRESS_1089866] a c e  at t his  visit:  
•  S A E  e v al u ati o n  
•  C o n c o mit a nt  m e di c ati o ns  p ot e nti all y r el at e d t o  S A Es  or  pr o hi bit e d  m e di c ati o ns  
•  Bl o o d  c oll e cti o n f or  a nti- C HI K V  n e utr ali z ati o n  
 
6. 1. [ADDRESS_1089867]  Visit ( ±  7  d a ys)  –  G r o u p  [ADDRESS_1089868] a c e  at t his  visit: Pri or t o  b o ost er  a d mi nistr ati o n:  
•  Uri n e  pr e g n a n c y t est (f e m al es  of  c hil d - b e ari n g p ot e nti al)  
•  C o nfir m ati o n  of  c o nti n u e d  eli gi bilit y  
•  C o n c o mit a nt  m e di c ati o ns  p ot e nti all y r el at e d t o  S A Es  or  pr o hi bit e d  m e di c ati o ns  
•  Vit al  si g ns 
•  Bl o o d  c oll e cti o n f or  a nti- C HI K V  n e utr ali z ati o n  
B o ost e r I nj e cti o n  –  G r o u p  [ADDRESS_1089869] er  a d mi nistr ati o n:  
•  A c ut e  o bs er v ati o n f or  u p t o  3 0  mi n ut es  
P X V X -C V -3 1 7 -0 0 1  P r ot o c ol  V 4. 0  2 2 M a y 2 0 2 0  C O N FI D E N TI A L  
P a g e  4 7   of  7 8   •  Vit al si g ns  aft er  at l e ast  3 0  mi n ut es  a n d  n o l at er t h a n  6 0  mi n ut es  
•  Iss ui n g  of  m e m or y ai d  
•  A E (s oli cit e d)  a n d  S A E  e v al u ati o n 
 
6. 1. [ADDRESS_1089870] ( ±  7  d a ys)  –  G r o u ps  [ADDRESS_1089871] a c e  at t his  visit:  
•  S A E  e v al u ati o n  
•  C o n c o mit a nt  m e di c ati o ns  p ot e nti all y r el at e d t o  S A Es  or  pr o hi bit e d  m e di c ati o ns  
•  Bl o o d  c oll e cti o n f or  A nti- C HI K V  n e utr ali z ati o n  
 
6. 1. 1 6   D a y  5 5 4,  p h o n e  visit ( +  3  d a ys)  –  G r o u p  [ADDRESS_1089872]. 
6. 1. 1 7   D a y  5 7 5 ( ±  3  d a ys)  –  G r o u ps  [ADDRESS_1089873] a c e  at t his  visit:  
•  R e vi e w  of t h e  m e m or y  ai d  
•  A E (s oli cit e d  a n d  u ns oli cit e d)  S A E  e v al u ati o n  
•  C o n c o mit a nt  m e di c ati o ns  
•  Bl o o d  c oll e cti o n f or  A nti- C HI K V  n e utr ali z ati o n  
 
6. 1. 1 8   D a y  7 6 0 (- 1 4/ + 9 0  d a ys)  –  G r o u ps  1,  [ADDRESS_1089874] a c e  at t his  visit:  
•  S A E  e v al u ati o n  
•  C o n c o mit a nt  m e di c ati o ns  p ot e nti all y r el at e d t o  S A Es  or  pr o hi bit e d  m e di c ati o ns  
•  Bl o o d  c oll e cti o n f or  a nti- C HI K V  n e utr ali z ati o n  
 
[ADDRESS_1089875] u d y p arti ci p ati o n  b ef or e  t h e D a y   7 6 0 visit  (f or  Gr o u ps  1,  4, a n d   8), 
b ef o r e  D a y  3 6 5 ( Gr o u ps  2,  3,  5,  6,  a n d  7)  a n d  b ef or e t h e  D a y  1 8 2  visit (f or  Gr o u p  9)  a n d  b ef or e t h e  D a y  2 9  visit (f or  Gr o u p  1 0)  will  b e r e q u est e d t o  u n d er g o  a n  E arl y  Dis c o nti n u ati o n visit.  
If t h e  visit  o c c urs  b ef or e  D a y  5 7 ( Gr o u ps  1- 9  o nl y)  a n d  D a y  2 9 ( Gr o u p  1 0  o nl y), t h e f oll o wi n g 
will  b e  c o n d u ct e d: 
•   R e vi e w  A Es  a n d  S A Es  
•   R e vi e w  C o n c o mit a nt  m e di c ati o ns  ass o ci at e d  wit h  n e w  or  o n g oi n g  A Es  a n d  a n y  S A Es  
•   Bl o o d  C oll e cti o n  f or: 
P X V X -C V -3 1 7 -0 0 1  P r ot o c ol  V 4. 0  2 2 M a y 2 0 2 0  C O N FI D E N TI A L  
P a g e  4 8   of  7 8   o   A nti -C HI K V  n e utr ali z ati o n  
o   A n ti-C HI K V  E LI S A ( Gr o u ps  1 - 9  o nl y) 
•   Uri n e  pr e g n a n c y t est f or f e m al es  of  c hil d - b e ari n g  p ot e nti al 
If  t h e  visit  o c c urs   wit hi n  [ADDRESS_1089876] e d: 
•   R e vi e w  of t h e  m e m or y  ai d  
•   A E (s oli cit e d)  e v al u ati o n 
If t h e  visit  o c c urs  aft er  D a y  5 7 ( Gr o u ps  1- 9  o nl y), t h e f oll o wi n g  will  b e  c o n d u ct e d: 
•   R e vi e w  S A Es  
•   R e vi e w  C o n c o mit a nt  m e di c ati o ns  ass o ci at e d  wit h  n e w  or  o n g oi n g  S A Es  
•   Bl o o d  C oll e cti o n  f or: 
o   A nti -C HI K V  n e utr ali z ati o n  
[ADDRESS_1089877] u g    A d mi nistr ati o n  ( F D A)  r e g ul ati o ns   all o w   c yt a p h er esis 
d o n ati o ns  at  a fr e q u e n c y  of  [ADDRESS_1089878] e m  ( pr ef err e d  o pti o n)  or  t h e   Tri m a    A c c el A ut o m at e d   Bl o o d  C o m p o n e nt C oll e cti o n  S yst e m  w hil e  c o n n e ct e d  t o Vist a ®  I nf or m ati o n S yst e ms 
p er t h eir  S O Ps.  
S u bj e cts  will   b e a d vis e d  t o  c o ns u m e  a w ell -b al a n c e d  m e al  a n d   a  [ADDRESS_1089879] e d  m a y r a n g e fr o m  6 0 0 -8 0 0  m Ls 
( d e p e n di n g  o n  d o n or  w ei g ht)  a n d t h e  a m o u nt  of r e d  bl o o d  c ell l oss  will  b e  a p pr o xi m at el y  [ADDRESS_1089880]’s   ar m  f or   p hl e b ot o m y   b y  st erili zi n g  t h e 
d esi g n at e d  i ns erti o n  sit e  o n  t h e  s u bj e ct’s  ar m  a n d  b y  e ns uri n g  a d e q u at e  v e n o us  a c c ess.   E a c h 
s u bj e ct s h o ul d e x p e ct  pl as m a   dr a wi n g t o t a k e  a p pr o xi m at el y  1- [ADDRESS_1089881]’s   ar m  f or   p hl e b ot o m y   b y  st erili zi n g  t h e 
d esi g n at e d  i ns erti o n  sit e  o n  t h e  s u bj e ct’s  ar m  a n d  b y  e ns uri n g  a d e q u at e  v e n o us  a c c ess.   E a c h 
s u bj e ct  s h o ul d  e x p e ct  l y m p h o c yt e  dr a wi n g  t o  t a k e  a p pr o xi m at el y  [ADDRESS_1089882] e d  will   b e  a p pr o xi m at el y  2 5 0 m Ls  ( d e p e n di n g  o n g e n d er,   h ei g ht,  w ei g ht, et c.). S u bj e cts  will   b e  m o nit or e d f or a n y  r e a cti o ns  or  dis c o mf ort  d uri n g a n d  aft er  t h e  pr o c e d ur e. S u bj e ct t ol er a n c e t o t h e  a nti c o a g ul a nt  m ust  b e  m o nit or e d  as w ell.  
P X V X -C V -3 1 7 -0 0 1  P r ot o c ol  V 4. 0  2 2 M a y 2 0 2 0  C O N FI D E N TI A L  
P a g e  5 0   of  7 8   7   S A F E T Y  
7. 1   D efi niti o ns  7. 1. 1  A d v e rs e  E v e nt  
A n  a d v ers e  e v e nt ( A E) is  a n y  u nt o w ar d  m e di c al  o c c urr e n c e i n  a st u d y  p arti ci p a nt, r e g ar dl ess  of 
t h e s us p e ct e d  c a us al r el ati o ns hi p  wit h st u d y  v a c ci n e. 
T h e  d efi niti o n  of  a n  A E i n cl u d es: 
•   A  n e w - o ns et s y m pt o m  or dis e as e  
•   A n  e x a c er b ati o n  of  a  pr e- e xisti n g s y m pt o m  or  dis e as e  
•   A  n e w - o ns et l a b or at or y  a b n or m alit y  c o nsi d er e d  b y t h e I n v esti g at or t o  b e  cli ni c all y 
si g nifi c a nt 
•   A  n e w - o ns et s y m pt o m  or  dis e as e t h at  o c c urs  as  a r es ult  of  a  pr ot o c ol-s p e cifi e d  pr o c e d ur e 
T h e  d efi niti o n  of  a n  A E  d o es  n ot  i n cl u d e: 
•   A  pr e - e xisti n g s y m pt o m  or  dis e as e t h at  d o es  n ot  w ors e n  d uri n g t h e st u d y ( e v e n if first 
dis cl os e d  b y t h e s u bj e ct  aft er t h e st art  of t h e st u d y) 
•   A  m e di c al  or s ur gi c al i nt er v e nti o n s u c h  as s ur g er y,  e n d os c o p y, t o ot h  e xtr a cti o n,  or 
tr a nsf usi o n ( alt h o u g h t h e  c o n diti o n l e a di n g t o t h e  pr o c e d ur e  or  a  c o m pli c ati o n fr o m t h e 
pr o c e d ur e  m a y  b e  a n  A E) *  
o   * A n y  c o m pli c ati o ns t h at  o c c ur s p e cifi c all y fr o m t h e  a p h er esis  pr o c e d ur es  will  b e 
c a pt ur e d  a n d r e c or d e d  as  A Es  
•   A n  u n c o m pli c at e d  pr e g n a n c y  
•   A  d osi n g  err or  wit h o ut  a n y r es ulti n g si g ns  or s y m pt o ms 
•   A n y  ot h er sit u ati o n  w h er e  a n  u nt o w ar d  m e di c al  o c c urr e n c e  h as  n ot  o c c urr e d ( e. g. 
h os pit ali z ati o n f or  c os m eti c  el e cti v e s ur g er y  or s o ci al  a d missi o ns) 
T h e  I n v esti g at or will  att e m pt  t o est a blis h   a  di a g n osis b as e d   o n si g ns, s y m pt o ms, a n d   ot h er cli ni c al 
i nf or m ati o n.  W h e n e v er  p ossi bl e, t h e I n v esti g at or  will r e p ort  a n  A E  as  a  di a g n osis r at h er t h a n  o n e or  m or e  si g ns  or  s y m pt o ms. If  a  cli ni c all y  si g nifi c a nt l a b or at or y  a b n or m alit y  m e ets t h e  d efi niti o n of  a n  A E,  a  di a g n osis  or  cli ni c al  si g ns  a n d  s y m pt o ms r at h er t h a n t h e  a b n or m al l a b or at or y fi n di n g 
s h o ul d  b e r e p ort e d if  p ossi bl e. If  n o  di a g n osis is  k n o w n  a n d  cli ni c al  si g ns  a n d  s y m pt o ms  ar e  n ot 
pr es e nt,   b ut t h e l a b or at or y a b n or m alit y  is cli ni c all y  si g nifi c a nt  b y its elf, t h e n it s h o ul d  b e r e p ort e d as t h e  A E.  
7. 1. 2   S oli cit e d  A d v e rs e  E v e nt  
A s oli cit e d  a d v ers e  e v e nt (s oli cit e d  A E) is  a  pr ot o c ol -s p e cifi e d  A E  a b o ut  w hi c h t h e I n v esti g at or 
or  d esi g n e e  pr o a cti v el y   as ks t h e s u bj e cts  d uri n g a  pr ot o c ol-s p e cifi e d ti m e  p eri o d. S oli cit e d  a d v ers e  
P X V X -C V -[ADDRESS_1089883] e mi c 
e v e nts  of  or al t e m p er at ur e  ≥  1 0 0. 4°  F,  c hills,  m al ais e, f ati g u e,  h e a d a c h e,  m y al gi a, j oi nt  p ai n,  a n d 
n a us e a.  
7. 1. 3   U ns oli cit e d  A d v e rs e  E v e nt  
A n  u ns oli cit e d  a d v ers e  e v e nt  ( u ns oli cit e d   A E)  is  a n   A E  t h at  is  s p o nt a n e o usl y  r e p ort e d  b y  t h e 
s u bj e ct  or  dis c o v er e d  b y t h e I n v esti g at or. 
7. 1. 4   S e ri o us  A d v e rs e  E v e nt  
A n  S A E is  a n  A E ( eit h er s oli cit e d  or  u ns oli cit e d)  w hi c h  m e ets  a n y  of t h e f oll o wi n g  crit eri a:  
•   R es ults i n  d e at h  
•   Is lif e-t hr e at e ni n g •   R e q uir es  h os pit ali z ati o n  or  pr ol o n gs  a n  e xisti n g  h os pit ali z ati o n  •   R es ults i n  a  p ersist e nt  cli ni c all y si g nifi c a nt  dis a bilit y  or  i n c a p a cit y •   Is  a  c o n g e nit al  a n o m al y  or  birt h d ef e ct  •   R e q uir es  m e di c al  or s ur gi c al i nt er v e nti o n t o  pr e v e nt  o n e  of t h e  a b o v e  o ut c o m es  •   I m p ort a nt  m e di c al e v e nt  
T h e I n v esti g at or  will  e v al u at e  all  A Es f or s eri o us n ess  usi n g t h e  a b o v e  crit eri a. 
 
“ Lif e -t hr e at e ni n g ” m e a ns  t h at, i n t h e  o pi [INVESTIGATOR_9384] o n  of t h e I n v esti g at or, t h e s u bj e ct w as  at  i m m e di at e ris k 
of  d e at h  fr o m t h e e v e nt  as  it o c c urr e d.  It  d o es  n ot m e a n  t h at t h e e v e nt   mi g ht  h a v e c a us e d  d e at h  h a d it  o c c urr e d i n  a  m or e s e v er e f or m. 
H os pit ali z ati o n  f or  o bs er v ati o n  or  f or  el e cti v e tr e at m e nt  of  a  pr e -e xisti n g  c o n diti o n t h at  di d  n ot 
w ors e n  d uri n g t h e st u d y is  n ot  c o nsi d er e d  a n  S A E. 
I mp ort a nt  m e di c al  e v e nts  m a y  b e  c o nsi d er e d s eri o us  at t h e  dis cr eti o n  of t h e I n v esti g at or. 
T h es e s eri o us n ess  crit eri a  als o  a p pl y t o t h e  St u d y  St o p pi n g  R ul es i n  S e cti o n  7. [ADDRESS_1089884] e d i n t h e  T o xi cit y  Gr a di n g  S c al e  will  b e  gr a d e d  as f oll o ws: 
•   Mil d ( Gr a d e  1)  –  N o i nt erf er e n c e  wit h  a cti vit y  
•   M o d er at e ( Gr a d e  2)  –  S o m e i nt erf er e n c e  wit h  a cti vit y  •   S e v er e ( Gr a d e  3)  –  Si g nifi c a nt;  pr e v e nts  d ail y  a cti vit y  
P X V X -C V -3 1 7 -0 0 1  P r ot o c ol  V 4. 0  2 2 M a y 2 0 2 0  C O N FI D E N TI A L  
P a g e  5 2   of  7 8   •   P ot e nti all y  Lif e -T hr e at e ni n g ( Gr a d e  4)  –  E R  visit  or  h os pit ali z ati o n  
7. 3   C a us alit y  Ass ess m e nt  
T h e I n v esti g at or  will  ass ess  all  A Es, i n cl u di n g  s oli cit e d  A Es, f or  c a us alit y (r el ati o ns hi p t o  st u d y 
v a c ci n e),  assi g ni n g  o n e  of  t h es e  t hr e e  c at e g ori es:   N ot   R el at e d,  P ossi bl y   R el at e d,  a n d  Pr o b a bl y R el at e d.  
A n  A E  will  b e  c o nsi d er e d  “ N ot  R el at e d ” t o  st u d y  v a c ci n e if  a n y  of t h e f oll o wi n g  c o n diti o ns  ar e 
m et:  
•   A n  u nr e as o n a bl e t e m p or al r el ati o ns hi p  b et w e e n  a d mi nistr ati o n  of t h e st u d y  v a c ci n e  a n d 
t h e  o ns et  of t h e  A E ( e. g., t h e  e v e nt  o c c urr e d  eit h er  b ef or e,  or t o o l o n g  aft er  a d mi nistr ati o n 
of t h e st u d y  v a c ci n e f or it t o  b e  c o nsi d er e d  r el at e d); 
•   A  c a us al r el ati o n s hi p  b et w e e n t h e st u d y  v a c ci n e  a n d t h e  A E is  bi ol o gi c all y i m pl a usi bl e 
( e. g. i nj ur y  as  a  p ass e n g er i n  a n  a ut o m o bil e a c ci d e nt);  
•   A  cl e ar  alt er n ati v e  c a us alit y f or t h e  A E is  pr es e nt ( e. g. t y pi c al  a d v ers e r e a cti o n t o  a 
c o n c o mit a nt  m e di c ati o n).  
A n  A E  will  b e  c o nsi d er e d  “ P ossi bl y r el at e d ” if t h er e is  a r e as o n a bl e  p ossi bilit y t h at t h e  A E  m a y 
h a v e  b e e n  c a us e d  b y t h e st u d y  v a c ci n e. 
A n  A E  will  b e  c o nsi d er e d  “ Pr o b a bl y r el at e d ” if t h er e is  e vi d e n c e t h at t h e  A E  w as  c a us e d  b y t h e 
st u d y  v a c ci n e. 
7. [ADDRESS_1089885]  t h e I n v esti g at or ( or d esi g n e e) 
i m m e di at el y.  All  s u bj e cts  e x p eri e n ci n g  a n  S A E  will b e  e v al u at e d  b y t h e I n v esti g at or  or  d esi g n e e as  s o o n  as is f e asi bl e f oll o wi n g t h e r e p ort  of t h e  S A E  b y t h e  s u bj e ct. I n t h e  e v e nt  of  a f at al  S A E, t h e  I n v esti g at or    m ust  pr o vi d e  t h e  S p o ns or   wit h  a n y  a v ail a bl e  p ost-m ort e m  fi n di n gs,  i n cl u di n g hist o p at h ol o g y. 
A d diti o n all y, t h e  S p o ns or  m a y r e q u est t h at t h e I n v esti g at or  p erf or m  or  arr a n g e f or t h e  c o n d u ct  of 
s u p pl e m e nt al i n v esti g ati o ns f or  o n e  or  m or e  A Es. 
P X V X -C V -[ADDRESS_1089886] er  i nj e cti o n.    T h e  t w o  r e p orti n g   p eri o ds  f or u ns oli cit e d    A Es  ar e:  i m m e di at el y  aft er  st u d y  v a c ci n e  a d mi nistr ati o n   o n    D a y  1  a n d  c o nti n u es t hr o u g h  D a y  5 7;  a n d i m m e di at el y  aft er  b o ost er i nj e cti o n  o n  D a y  5 4 7  a n d  c o nti n u es t hr o u g h  D a y 
5 7 5.  A Es  t h at  c orr es p o n d t o s oli cit e d A E  t er ms  b ut o c c ur   o utsi d e  of ( or  c o nti n u e p ast)  t h e s oli cit e d 
A E  c oll e cti o n  p eri o ds  ar e  als o  c oll e ct e d  t hr o u g h  t h e  u ns oli cit e d    A E  r e p orti n g  p eri o ds.    T h e r e p orti n g  p eri o d f or  S A Es  b e gi ns  at t h e ti m e  of i nf or m e d  c o ns e nt  a n d  c o nti n u es f or t h e  d ur ati o n of st u d y  p arti ci p ati o n.  
T h e  s u m m ar y  of t h e r e p orti n g  p eri o ds f or  Gr o u ps  2,  3,  5,  6,  a n d  7 is  d es cri b e d i n  Fi g ur e  3  a n d i n 
F i g ur e  4 f or  Gr o u ps  1,  4,  a n d  8,f or  Gr o u p  9 i n Fi g ur e  5   a n d  Gr o u p  1 0 i n  Fi g ur e  6. 
Fi g u r e  3:  S af et y  E v e nts  R e p o rti n g  P e ri o ds ( G r o u ps  2,  3,  5,  6,  a n d  7) 
 
 
 
 
 
 
 
 
 
 1 S cr e e ni n g  Tr e at m e nt  &  O bs er v ati o n  F oll o w  u p  
D a y:  [ADDRESS_1089887]’s  s o ur c e  d o c u m e nts  a n d  e nt er 
all  A Es i n t h e  a d v ers e  e v e nt  e C R F  wit hi n  3  c al e n d ar  d a ys  of  a w ar e n ess.  
All  A Es s h o ul d i n cl u d e: 
•  E v e nt  t er m 
•  St art  a n d st o p  d at e  
•  S e v erit y  
•  S eri o us n ess ( Y es/ N o)  a n d if  Y es,  S eri o us n ess  crit eri a  m et  
•  R el ati o ns hi p t o st u d y  v a c ci n e  
•  A cti o n t a k e n i n r es p o ns e t o t h e  A E  
•  A cti o n t a k e n  wit h  St u d y  Dr u g  
 
[ADDRESS_1089888] i n cl u d e 
a n  alt er n at e  c a us alit y.  
I n  or d er  t o  a v oi d  d el a ys  i n  i niti al  r e p orti n g,  a d diti o n al  i nf or m ati o n  r e g ar di n g  t h e  S A E    m a y  b e 
pr o vi d e d  as  a  f oll o w -u p  r e p ort.   T h e  I n v esti g at or    m a y  als o    m o dif y  t h e  di a g n osis,  s eri o us n ess, a n d/ or  c a us alit y  ass ess m e nt  b as e d  o n t his i nf or m ati o n. 
T h e    M M    will  n otif y  t h e  I n v esti g at or  of   S A Es  t h at    m e et  crit eri a  f or  e x p e dit e d  r e p orti n g  t o 
r e g ul at or y  a ut h oriti es.  T h e  I n v esti g at or is  r es p o nsi bl e  f or  n otif yi n g  t h e  a p pli c a bl e  I R B  of t h es e e v e nts  a n d  a d h eri n g t o  a n y  o t h er  a p pli c a bl e l o c al r e p orti n g r e q uir e m e nts. 
T h e  S p o ns or  will r e p ort  a d v ers e  e v e nts t o  F D A i n  a c c or d a n c e  wit h  [ADDRESS_1089889] e d  a d v ers e r e a cti o ns ( S U S A Rs)  n o l at er t h a n  1 5 c al e n d ar  d a ys  aft er  d et er mi ni n g  t h at t h e i nf or m ati o n q u alifi es f or  e x p e dit e d r e p orti n g. 
It is  als o t h e r es p o nsi bilit y  of t h e  M M t o  m a k e t h e d et er mi n ati o n  of  w hi c h  S A Es  ar e  “s eri o us  a n d 
u n e x p e ct e d s us p e ct e d  a d v ers e r e a cti o ns ” ( S U S A Rs),  as  d efi n e d i n  2 1  C F R  3 1 2. 3 2. 
P X V X -C V -3 1 7 -0 0 1  P r ot o c ol  V 4. 0  2 2 M a y 2 0 2 0  C O N FI D E N TI A L  
P a g e  5 7   of  7 8   •  S us p e ct e d  a d v ers e r e a cti o n  m e a ns  a n y  A E f or  w hi c h t h er e is  a r e as o n a bl e  p ossi bilit y t h at 
t h e  dr u g  c a us e d t h e A E.  
•  U n e x p e ct e d  a d v ers e r e a cti o n  m e a ns  a n  A E t h at is  n ot list e d i n t h e I n v esti g at or’s   Br o c h ur e 
or is  n ot list e d  at t h e s p e cifi cit y  or s e v erit y t h at  h as  b e e n   o bs er v e d. 
All  S U S A Rs,  as  d et er mi n e d   b y t h e I N D  S p o ns or, will   b e r e p ort e d t o F D A  a n d  will   b e  pr o vi d e d t o 
all  p arti ci p ati n g I n v esti g at ors  b y t h e I N D  S p o ns or. 
F or  f urt h er i nf or m ati o n  r e g ar di n g  S A E  r e p orti n g,  pl e as e  r ef er t o t h e  P X V X -C V - [ADDRESS_1089890] a n ( S M P).  
[ADDRESS_1089891] a n ( S M P). 
P X V X -C V -3 1 7 -0 0 1  P r ot o c ol  V 4. 0  2 2 M a y 2 0 2 0  C O N FI D E N TI A L  
P a g e  5 8   of  7 8   7. 7. 5   S af et y  E v e nts  R el at e d t o  A p h e r esis  
A Es  r el at e d t o  a p h er esis  ( pl as m a p h er esis  a n d l e u k a p h er esis)  pr o c e d ur es  will  b e  c oll e ct e d  at t h e 
D a y  5 7  a n d  D a y  1 8 2  visits f or  Gr o u p  9  a n d ( pl as m a p h er esis)  at  D a y  2 2 f or  Gr o u p  1 0.  S A Es  a n d A Es t h at r es ult i n  c h a n g es t o t h e  a p h er esis  pr o c e d ur e(s) (s u c h  as  e arl y t er mi n ati o n  of  c oll e cti o n) m ust  b e r e p ort e d  wit hi n  2 4  h o urs  of  a w ar e n ess t o t h e  M M. 
7. 8   M e di c al   M o nit o r 
T h e  M e di c al  M o nit or ( M M)  will  pr o vi d e s af et y  o v ersi g ht f or t h e st u d y.  T h e  M M  will r e vi e w 
bli n d e d st u d y  d at a  a n d  ass ess  c a us alit y  of  S A Es  o n  a n  o n g oi n g  b asis. 
N a m e:   
A d dr ess:  
 
  
  
  
 
7. [ADDRESS_1089892] a n ( S M P).  
P X V X -C V -[ADDRESS_1089893] eti o n   G ui d eli n es. D et ails   o n d at a 
h a n dli n g  will  b e  d es cri b e d i n t h e i nt er n al s p o ns or’s  D at a  M a n a g e m e nt  Pl a n  ( D M P). 
[ADDRESS_1089894] u d y t o  v erif y  a d h er e n c e t o t h e  pr ot o c ol;  c o m pl et e n ess,  a c c ur a c y,  a n d 
c o nsist e n c y   of t h e d at a;  a n d  a d h er e n c e  t o l o c al r e g ul ati o ns  o n t h e  c o n d u ct  of cli ni c al  r es e ar c h. T h e 
I n v esti g at or  m ust  m a k e  s o ur c e  d o c u m e nt ati o n  a c c essi bl e t o t h e  S p o ns or  or  d esi g n e e  as  n e e d e d t o v erif y  t h e  i nf or m ati o n  i n  t h e  e C R Fs.   T h e  I n v esti g at or  a gr e es  t o  c o o p er at e   wit h  t h e  S p o ns or  or d esi g n e e t o  e ns ur e t h at  a n y  pr o bl e ms  d et e ct e d i n t h e  c o urs e  of  d at a  m o nit ori n g  ar e r es ol v e d. 
[ADDRESS_1089895]  p er mit t h e  S p o ns or  a n d/ or  d esi g n e e,  r e g ul at or y  a g e n ci es,  a n d/ or t h e  I R B 
dir e ct  a c c ess  t o f a ciliti es a n d  st u d y  d o c u m e nt ati o n f or t h e  p ur p os e  of a u diti n g st u d y c o n d u ct. Dir e ct a c c ess i n cl u d es  e x a mi ni n g,  a n al y zi n g,  v erif yi n g,  a n d r e pr o d u ci n g  a n y r e c or ds  a n d r e p orts t h at  ar e n e e d e d f or t h e  e v al u ati o n  of t h e st u d y. 
P X V X -C V -[ADDRESS_1089896]  8 0 %  p o w er,  at  al p h a = 0. [ADDRESS_1089897] a n d ar d  r es p o ns e  of 7 0 %  i n  tr e at m e nt  gr o u p  1  vs.  9 5 %  i n  a n y  of  t h e  ot h er  tr e at m e nt  gr o u ps.   T h e  f or m ul ati o n  a n d s c h e d ul e  us e d i n  gr o u p  1  ( 2 0  m c g  V L P  u n a dj u v a nt e d  at  D a y  1  a n d  D a y  2 9) is t h e  r e gi m e n t h at r es ult e d  i n  1 0 0 %  of  s u bj e cts   wit h  s er o c o n v ersi o n  at  [ADDRESS_1089898] u d y  V R C  3 1 1. 
B as e d  o n t h es e  pri or  d at a  a n d t h e li k el y  u ni v ers al  r es p o ns e i n t his tri al’s  R ef er e n c e  Gr o u p, it is 
u nli k el y  t h at t h e  pr o p orti o n-b as e d  a n al ys es  will   b e a bl e  t o dis cri mi n at e  b et w e e n  tr e at m e nt  gr o u ps. F or t his r e as o n, t h e tr e at m e nt  gr o u p  G M Ts  will  als o  b e  us e d f or  d os e  s el e cti o n. 
I n t h e tit er-b as e d  c o m p aris o ns,  wit h  a  s a m pl e  si z e  of  [ADDRESS_1089899] a n d ar d 
d e vi ati o n  ( S D) esti m at e  of   0. 5 2 5 (l o g 1 0 s c al e) t h er e is  8 0 %  p o w er, at   al p h a = 0. [ADDRESS_1089900]. 
T h e   si z e   of  t h e   o p e n -l a b el   gr o u p  ( Gr o u p   9)  is   b as e d   o n   pr a cti c al,  r at h er  t h a n   st atisti c al, 
c o nsi d er ati o ns.   T w e nt y  s u bj e cts    will  pr o vi d e  a d e q u at e  pl as m a  t o  f ut ur e  n o n -cli ni c al  p ur p os es wit h o ut  n e e dl essl y  e x p osi n g  a d diti o n al s u bj e cts t o t h e  m or e i n v asi v e  pr o c e d ur es. 
T h e  si z e   of  t h e   o p e n -l a b el   gr o u p  ( Gr o u p   1 0)  is   b as e d   o n   pr a cti c al,  r at h er  t h a n  st atisti c al, 
c o nsi d er ati o ns.  T e n  s u bj e cts will   pr o vi d e a d e q u at e  pl as m a  t o f ut ur e  n o n-cli ni c al   p ur p os es  wit h o ut n e e dl essl y  e x p osi n g  a d diti o n al s u bj e cts t o t h e  m or e i n v asi v e  pr o c e d ur es. 
 
 
[ADDRESS_1089901] er  p eri o d  fr o m   D a y  5 4 7  t o   D a y  7 6 0  f or    Gr o u p  4.    Gr o u p  1 0  is  o nl y  f oll o w e d 
t hr o u g h  D a y  2 9. 
9 .3   T r e at m e nt  G r o u ps  
S u bj e cts   will  b e  r a n d o mi z e d  e q u all y  i nt o  8  tr e at m e nt  gr o u ps  of  v ar yi n g  d os es  ( a n d  n u m b er  of 
d os es),  a dj u v a nt e d  vs.  n o n a dj u v a nt e d,  a n d  v a c ci n ati o n i nt er v al  of  eit h er  2  or  4  w e e ks f or  a cti v e 
P X V X -C V -3 1 7 -0 0 1  P r ot o c ol  V 4. 0  2 2 M a y 2 0 2 0  C O N FI D E N TI A L  P a g e  6 3   of  7 8   •  H a v e  n ot r e c ei v e d  a  pr o hi bit e d  m e di c ati o n.  
•  Pr o vi d e  e v al u a bl e s er u m s a m pl e r es ults f or  b as eli n e, t h e r el e v a nt  p ost- v a c ci n at i o n ti m e 
p oi nts,  a n d  wit hi n t h e r e q uir e d ti m e fr a m es ( Gr o u ps  1- 8  o nl y): 
o   B as eli n e:  D a y  [ADDRESS_1089902] u d y  v a c ci n e  a d mi nistr ati o n  
o   D a y  5 7:  D a y  [ADDRESS_1089903] e risti cs:  T h e   d e m o gr a p hi c   a n d   b as eli n e 
c h ar a ct eristi cs  will  b e s u m m ari z e d  a c c or di n g t o tr e at m e nt  gr o u p  a n d  o v er all.  
A g e,   h ei g ht,  w ei g ht, a n d   b o d y m ass  i n d e x at  e nr oll m e nt will   b e s u m m ari z e d  b y r e p orti n g t h e m e a n,  
st a n d ar d  d e vi ati o n,    m e di a n,    mi ni m u m  a n d    m a xi m u m,  a n d  c al c ul at e d  b y  tr e at m e nt  gr o u p  a n d 
o v er all.  
T h e  fr e q u e n ci es  a n d  p er c e nt a g es  of  s u bj e cts  b y  s e x,  r a c e,  a n d  et h ni cit y    will  b e  pr es e nt e d  b y 
tr e at m e nt   gr o u p   a n d   o v er all.    D e m o gr a p hi c   d at a    will   b e   t a b ul at e d   f or   t h e    R a n d o mi z e d, I m m u n o g e ni cit y  E v al u a bl e,  a n d  S af et y  p o p ul ati o ns. 
9 .5   S af et y   A n al ysis 
A n al ysis  of  E xt e nt  of  E x p os u r e 
 
T h e  fr e q u e n ci es a n d  p er c e nt a g es   of s u bj e cts wit h  v a c ci n ati o ns,  a n d  t h e ti mi n g  of t h e  v a c ci n ati o ns, 
will  b e s u m m ari z e d  b y tr e at m e nt  gr o u p f or t h e  R a n d o mi z e d  p o p ul ati o n. 
All s af et y  a n al ys es  will  b e  b as e d  o n t h e  S af et y  p o p ul ati o n. 
9. 5. 1   S oli cit e d  A Es  
Wit h t h e  e x c e pti o n  of  r e d n ess  a n d  s w elli n g,  all  s oli cit e d  A Es  will  b e  s u m m ari z e d  a c c or di n g t o 
s e v erit y  gr a di n g s c al es  d efi n e d i n  S e cti o n  7. 2  fr o m  “ mil d ” t o  “ p ot e nti all y lif e-t hr e at e ni n g. ” 
S oli cit e d  A Es  will  b e  r e c or d e d  d ail y  u ntil  [ADDRESS_1089904] ur e d  m e m or y  ai d. 
T h e  a n al ys es  of  s oli cit e d   A Es  ( a n y  e v e nt,  aft er  a n y  i nj e cti o n,  a n d  aft er  e a c h  i nj e cti o n)   will  b e p erf or m e d  b y  m a xi m u m s e v erit y  a n d  b y tr e at m e nt  gr o u p. I n  a d diti o n, s oli cit e d  A Es  o n g oi n g  aft er [ADDRESS_1089905] e mi c s oli cit e d A E o v er all  a n d  at  e a c h ti m e  p oi nt  will  als o  b e  pr es e nt e d.  
T h e  s e v erit y  of r e d n ess  a n d  s w elli n g r e c or d e d  as  di a m et ers ( m m)  will  b e  s u m m ari z e d  a c c or di n g 
t o  c at e g ori es  b as e d  o n t h e l ar g est  di a m et er li n e ar  m e as ur e m e nt  w h e n t h e l o c al r e a cti o n is  pr es e nt: 
P X V X -C V -3 1 7 -0 0 1  P r ot o c ol  V 4. 0  2 2 M a y 2 0 2 0  C O N FI D E N TI A L  P a g e  6 4   of  7 8   •  Gr a d e  0/ a bs e nt  =  0 - 2 4 m m.  
•  Gr a d e  1/ mil d  > 2 4- 5 0  m m.  
•  Gr a d e  2/ m o d er at e  > 5 0 - 1 0 0 m m.  
•  Gr a d e  3/s e v er e  > 1 0 0  m m.  
 
E v e nts r e p ort e d  as  n ot  pr es e nt ( 0  m m is  e nt er e d)  will  b e r e p ort e d  as  Gr a d e  0. 
T h e f oll o wi n g  cl assifi c a ti o ns  ar e  us e d i n t h e s u m m ari es: Gr a d e  0 ( 0 - 2 4  m m),  A n y ( > 2 4- 5 0  m m,  > 5 0- 1 0 0  m m,  > 1 0 0  m m) 
T h e f oll o wi n g s u m m ari es  of s oli cit e d  e v e nts  will  b e  p erf or m e d:  
1.   S oli cit e d  e v e nts  b y  d a y  p ost-i nj e cti o n f or  e a c h i nj e cti o n, f or  e a c h  e v e nt  a n d f or  a n y  e v e nt.  
2.   Ti m e  of first  o ns et  of s oli cit e d  a d v ers e  e v e nts,  aft er  e a c h i nj e cti o n  a n d  aft er  a n y  i nj e cti o n, 
f or  e a c h  e v e nt  a n d  a n y  e v e nt. 
3.   S oli cit e d  a d v ers e  e v e nts  b y  m a xi m u m  e v e nt s e v erit y,  aft er  e a c h i nj e cti o n  a n d  aft er  a n y 
i nj e cti o n, f or  e a c h  e v e nt  a n d f or  a n y e v e nt.  
4.   D ur ati o n  of s oli cit e d  a d v ers e  e v e nts,  aft er  e a c h i nj e cti o n, f or  e a c h  e v e nt  a n d  a n y  e v e nt.  
5.   S oli cit e d  a d v ers e  e v e nts,  o c c urr e n c e  of  at l e ast  o n e  e v e nt  b y  c at e g or y (l o c al,  s yst e mi c), 
aft er  e a c h i nj e cti o n  a n d  aft er  a n y  i nj e cti o n. 
F or  e a c h   of t h e ti m e  p oi nts  or ti m e i nt er v als pr es e nt e d  i n t h e s u m m ari es,  o nl y s u bj e cts wit h  at  l e ast 
o n e  o bs er v ati o n (i. e.,  a n y   n o n-missi n g  v al u es   b ut  e x cl u di n g “ N ot   d o n e/ u n k n o w n ”) f or t h e s oli cit e d a d v ers e  e v e nts  will  b e  s u m m ari z e d.  
9. 5. [ADDRESS_1089906] e m  or g a n  cl ass  ( S O C).    All r e p ort e d    A Es,  as    w ell  as    A Es  j u d g e d  b y  t h e  I n v esti g at or  as  at  l e ast  p ossi bl y  r el at e d  t o  st u d y 
v a c ci n e,   will  b e  s u m m ari z e d  b y  tr e at m e nt  gr o u p,  a c c or di n g  t o  S O C  a n d  pr ef err e d  t er m   wit hi n 
S O C.  W h e n  a n  u ns oli cit e d  A E  o c c urs  m or e t h a n  o n c e  f or  a  s u bj e ct, t h e  m a xi m u m  s e v erit y  a n d str o n g est r el ati o ns hi p t o t h e tr e at m e nt  gr o u p  will  b e  c o u nt e d. 
O nl y tr e at m e nt -e m er g e nt  A Es  will  b e  s u m m ari z e d, i. e.,  e x cl u di n g t h os e  aft er  a  s u bj e ct  h as  gi v e n 
i nf or m e d  c o ns e nt,  b ut  b ef or e  v a c ci n ati o n.  T h e  s el e cti o n  of  u ns oli cit e d  A Es  a n d t h eir  assi g n m e nt 
t o ti m e i nt er v als  will  b e  d o n e  b y  d a y  of  o ns et  a n d  n ot  b y  d a ys  o n g oi n g/ p ersisti n g. 
P X V X -C V -3 1 7 -0 0 1  P r ot o c ol  V 4. 0  2 2 M a y 2 0 2 0  C O N FI D E N TI A L  P a g e  6 5   of  7 8   U ns oli cit e d  A Es  will  b e s u m m ari z e d  b y  al p h a b eti c  S O C  a n d  pr ef err e d t er m  as f oll o ws: 
•  A n y  u ns oli cit e d  A E  
•  P ossi bl y  or  pr o b a bl y r el at e d  u ns oli cit e d  A Es  
•  S A Es  •  P ossi bl y  or  pr o b a bl y r el at e d  S A E  •  U ns oli cit e d  A E l e a di n g t o  wit h dr a w al  
•  A n y  A E l e a di n g t o  d e at h  
 
Listi n gs  of  all  A Es  will  b e  pr o vi d e d  b y s u bj e ct. 
 
C o m bi n e d  S oli cit e d  a n d  U ns oli cit e d  A d v ers e  E v e nts 
S oli cit e d    A Es  c o nti n ui n g  b e y o n d  7  d a ys  aft er  a n y  i nj e cti o n    will  b e  c o d e d  b y    M e d D R A  a n d 
c o m bi n e d    wit h  t h e  u ns oli cit e d    A Es.    A  s u m m ar y  of  s u bj e cts    wit h  all  c o m bi n e d  s oli cit e d  a n d u ns oli cit e d  A Es,  b y  S O C  a n d  pr ef err e d t er m,  will  b e  pr o vi d e d  as  w ell. 
9. 5. 3   A n al ysis  of  Ot h e r  S af et y  D at a  
T h e  fr e q u e n ci es  a n d  p er c e nt a g es  of  c o n c o mit a nt    m e di c ati o ns   will  b e  t a b ul at e d  o v er all  a n d  b y 
tr e at m e nt  gr o u p.  M e di c ati o ns  will  b e  c o d e d  usi n g t h e  W H O D R U G  di cti o nar y.  
9. 6   I m m u n o g e ni cit y  A n al ysis 
G M T/ G M R:  
 
T h e  G M Ts  a n d  G M Rs  ass o ci at e d  wit h t h e  pri m ar y  o bj e cti v e  will  b e  a n al y z e d  vi a li n e ar  m o d el. 
T h e  pri m ar y  m o d el is  a n  a n al ysis  of  v ari a n c e ( A N O V A),  wit h l o g arit h mi c all y -tr a nsf or m e d  a nti- 
C HI K V tit ers  (l o g 1 0)  as t h e  d e p e n d e nt  v ari a bl e  a n d tr e at m e nt  gr o u p  a n d  st u d y  sit e  as t h e  fi x e d 
eff e cts i n t h e  m o d el.  T h e  r es ults i n cl u d e d i n t h e  m ai n t a bl es  of t his  r e p ort  will  b e  b as e d  o n t his 
b asi c    A N O V A    m o d el.    As  a  s e c o n d ar y  a n al ysis,  i n   or d er  t o  r e m o v e  t h e  eff e ct   of   b as eli n e 
c o n c e ntr ati o n  o n t h e  G M Ts,  a n  a n al ysis  of  c o v ari a n c e  ( A N C O V A)  will  als o  b e  p erf or m e d.  T h e 
A N C O V A i n cl u d es tr e at m e nt  gr o u p  a n d  st u d y  sit e  as  t h e  fi x e d  eff e cts  a n d l o g [ADDRESS_1089907]  s q u ar e  m e a ns  a n d t h eir  9 5 %  CIs  c al c ul at e d  b as e d  o n t h e  A N O V A  a n d  A N C O V A  will 
b e  b a c k tr a nsf or m e d  a n d r e p ort e d  as t h e  gr o u p  G M T  v al u es ( a dj ust e d f or t h e  m e a n  b as eli n e i n t h e c as e  of t h e  A N C O V A).  
C o m p aris o ns  b et w e e n  r el ev a nt  gr o u ps  will   b e b as e d   o n t h e esti m at e d  a dj ust e d  G M Ts  m e as ur e d  at 
D a y   [ADDRESS_1089908]  G M R  will  b e r el ati v e t o  D a y  5 4 7. 
S p e cifi c all y, t esti n g  will  b e  d o n e  of t h e  n ull  h y p ot h esis: 
 
H0:  µi =  µ j 
a g ai nst t h e  alt er n ati v e  h y p ot h esis  of i n e q u alit y.  H er e  µ i a n d  µ j d e n ot e t h e  p o p ul ati o n  m e a ns f or 
a n y t w o  of t h e tr e at m e nt  gr o u ps.  T h e  m ai n  c o m p aris o n  of i nt er est  will  b e t h e t w o  d os e  2 0  m c g 
C HI K V -V L P  ( u n a dj u v a nt e d)  gr o u p  v ers us  a n y  of  t h e  a dj u v a nt e d  gr o u ps.   H o w e v er,  ot h er  p air - wis e  c o m p aris o ns  wi ll  als o  b e  of i nt er est.  All t ests  will  b e  c arri e d  o ut  at  a  2-si d e d  si g nifi c a n c e l e v el  of  0. [ADDRESS_1089909] a blis h i nf er e nti al  v al u es. 
T h e  G M Ts  a n d  G M Rs (r el ati v e t o  D a y  1  or  5 4 7,  as  a p pli c a bl e)  b as e d  o n  a nti b o d y tit ers 
m e as ur e d  at  all  ot h er  pr ot o c ol- s p e cifi e d ti m e  p oi nts  will  b e  a n al y z e d  as  d es cri b e d  a b o v e f or  D a y  [ADDRESS_1089910]  v a c ci n ati o n  at  e a c h ti m e  p oi nt  will  b e  vis u all y  ass ess e d.  
T hr es h ol d  a n al ys es : 
 
T h e  p er c e nt a g e  of s u bj e cts  a c hi e vi n g s p e cifi e d t hr es h ol ds ( e. g.,  ≥  1 0,  1 0 0,  5 0 0,  1 0 0 0, f o ur-f ol d 
ris e  o v er  b as eli n e),  a n d  ass o ci at e d  Wils o n  9 5 %  CI,  will b e  c al c ul at e d f or t h e  D a y  5 7  visit  d at a 
f or  e a c h tr e at m e nt  gr o u p.  Diff er e n c es  b et w e e n  p air-wis e tr e at m e nt  gr o u ps  will  b e  d et er mi n e d  vi a Fis h er’s  E x a ct  t est. 
D os e s el e cti o n  crit eri a : 
 
T h e  pri m ar y  ass ess m e nt    will  b e  b as e d  o n  a nti b o d y  tit ers    m e as ur e d  at    D a y  [ADDRESS_1089911] is  si g nifi c a nt 
( 0. 0 5 si g nifi c a n c e  l e v el), a n d  if t h e p er c e nt a g e   of s u bj e cts i n t h e  d o mi n a nt  gr o u ps t h at w er e   a b o v e a  cli ni c all y -r el e v a nt tit er l e v el  w as  n o l ess t h a n  7 5 %.  W hil e t h e  cli ni c all y-r el e v a nt l e v el is  n ot  y et est a blis h e d,  t h e  s p e cifi c  t hr es h ol ds  a n al ys es  ar e  e x p e ct e d  t o  br a c k et  t h e  p ot e nti all y  pr ot e cti v e l e v els. 
T h e r e v ers e  c u m ul ati v e  distri b uti o n  of  a nti b o d y tit ers f or  all tr e at m e nt  gr o u ps  will  b e  pr o d u c e d t o ai d i n t h e s el e cti o n  of t h e f ut ur e  d os e  gr o u p(s) t o  us e i n t h e  cli ni c al  pr o gr a m. 
F or  gr o u ps t h at  a p p e ar i n disti n g uis h a bl e, s el e cti o n  of  a f or m ul ati o n  will  b e  b as e d  o n  a  c o m bi n e d 
b o d y  of  e vi d e n c e  o bt ai n e d fr o m t h e  G M T  v al u es,  p er c e nt a g e  of r es p o n d ers, s af et y  pr ofil es  a n d 
a d diti o n al s u m m ar y  v ari a bl es if  d e e m e d  n e c ess ar y.  
P X V X -C V -[ADDRESS_1089912] or at or y  a n al ys es  b as e d  o n t h e r es ults fr o m t h e  P B M C  c oll e cti o n  a n d  a p h er esis  pr o c e d ur es 
will  b e  d es cri pti v e  o nl y ( m e a n,  m e di a n,  S D,  mi n/ m a x f or  c o nti n u o us  v ari a bl es  a n d fr e q u e n c y 
c o u nts  a n d  p er c e nt a g es f or  c at e g ori c al  v ari a bl es).  
9. 7   I nt e ri m  A n al ys es  
T h er e  will   b e  a s af ety  a n d  i m m u n o g e ni cit y i nt eri m a n al ysis  f or t h e s el e cti o n  of f or m ul ati o n(s)  a n d 
s c h e d ul e  b as e d  o n t h e  d at a  c oll e ct e d t hr o u g h  D a y  [ADDRESS_1089913]  l e v el.    Aft er  t h e  i nt eri m  a n al ysis,  o n e 
e xisti n g  or  n e w  gr o u p ( Gr o u p  9)  will  b e  c o nsi d er e d f or  a  pl as m a p h er esis  a n d  l e u k a p h er esis. 
F or f urt h er i nf or m ati o n,  pl e as e r ef er t o t h e  P X V X- C V - [ADDRESS_1089914] a n ( S A P).  
P X V X -C V -[ADDRESS_1089915] e nt    wit h  I C H    G o o d 
Cli ni c al  Pr a cti c e ( G C P)  G ui d eli n es  a n d  a p pli c a bl e l o c al r e g ul at or y r e q uir e m e nts  a n d l a ws.  
[ADDRESS_1089916] u d y ( pr ot o c ol, i nf or m e d  c o ns e nt f or m, r e cr uiti n g  m at eri als,  a n d  a n y  d o c u m e nts s e e n  b y t h e 
s u bj e ct) will   b e r e vi e w e d a n d   a p pr o v e d  b y a n  I R B  a p pr o pri at e t o e a c h  st u d y sit e. S u bj e cts  will   n ot 
b e   r e cr uit e d,   c o ns e nt e d,   s cr e e n e d,   or   e nr oll e d   u ntil   t h e   I R B   h as   a p pr o v e d   t h e   r e q uir e d d o c u m e nt ati o n.  I n   a d diti o n,  t h e  I R B    will  r e vi e w   a m e n d m e nts  t o  t h e   pr ot o c ol   b ef or e  t h eir i m pl e m e nt ati o n. 
T h e  I n v esti g at or  will  r et ai n  all  c orr es p o n d e n c e  wit h t h e  I R B  i n t h e tri al  m ast er  fil e  ( T M F)  a n d 
f or w ar d  c o pi [INVESTIGATOR_166769] I R B  a p pr o v als t o t h e  S p o ns or. 
[ADDRESS_1089917] er i nf or m e d  c o ns e nt f or m (I C F) t e m pl at e t o  e a c h sit e 
f or  d e v elo p m e nt  of  a  sit e -s p e cifi c  I C F.   At  t h e  I n v esti g at or’s  dis cr eti o n,  t h e  sit e   m a y  d e v el o p  a s e p ar at e I C F f or  St e p  [ADDRESS_1089918] u d y  p arti ci p a nt’s  s atisf a cti o n. T h e  p ot e nti al  st u d y  p arti ci p a nt   will  t h e n  d e ci d e    w h et h er  or  n ot  t o  p arti ci p at e  i n  t h e  tri al.   T h e 
I n v esti g at or,  or  a  q u alifi e d  p ers o n  d esi g n at e d  b y  t h e  I n v esti g at or,   will  o bt ai n   writt e n  i nf or m e d 
c o ns e nt fr o m  e a c h st u d y  p arti ci p a nt  b ef or e  a n y st u d y- s p e cifi c  a cti vit y is  p erf or m e d. 
T h e  I n v esti g at or   will  r et ai n  t h e  ori gi n al  a n d  a n y  a m e n d e d  si g n e d  a n d  d at e d  I nf or m e d   C o ns e nt 
F or m(s)  at t h e  st u d y sit e  a n d  pr o vi d e  a  c o p y t o  e a c h st u d y  p arti ci p a nt. 
P X V X -C V -[ADDRESS_1089919] e m e nt e d: 
 
•   T h e  c o n d u ct  of t h e st u d y  will  b e i n  a c c or d a n c e  wit h st at e  a n d l o c al  tr a v el 
li mit ati o ns/r estri cti o ns. 
•   St u d y st aff  at t h e  pl as m a  c e nt er  will t a k e  a p pr o pri at e  pr e c a uti o ns t o  pr ot e ct st u d y 
p arti ci p a nts.  
•   S af et y  ass ess m e nts  will  b e  p erf or m e d  b y  p h o n e  c all  w h e n   a p pr o pri at e. 
•   If tr a v el r estri cti o ns  or  C O VI D-[ADDRESS_1089920] aff a n d  p arti ci p a nts  a n d   m o nit or  pr ot o c ol 
d e vi ati o ns  d u e t o  C O VI D- 1 9 ill n ess  a n d/ or  C O VI D- [ADDRESS_1089921]’s  a n o n y mit y  is  m ai nt ai n e d.  O n  e C R Fs  a n d  ot h e r 
d o c u m e nts  s u b mitt e d t o t h e  S p o ns or  a n d/ or its  d esi g n e e,  s u bj e cts  m ust  b e i d e ntifi e d  b y  s u bj e ct n u m b er  o nl y.  F or  d o c u m e nts t h at  ar e  n ot f or  s u b missi o n t o t h e  S p o ns or  a n d/ or its  d esi g n e e ( e. g., 
si g n e d I C Fs), t h e I n v esti g at or  m ust m ai nt ai n  t h es e  d o c u m e nts se c ur el y  a n d  i n c o m pli a n c e  wit h  all 
f e d er al l a ws  a n d r e g ul ati o ns,  a n d I C H  G C P  G ui d eli n es. 
[ADDRESS_1089922] e m e nt ati o n. 
A m e n d m e nts,  i n cl u di n g   d es cri pti o ns   a n d  r ati o n al es,    will   b e   d o c u m e nt e d  i n   a   S u m m ar y   of 
C h a n g es. 
P X V X -C V -3 1 7 -0 0 1  P r ot o c ol  V 4. 0  2 2 M a y 2 0 2 0  C O N FI D E N TI A L  P a g e  7 3   of  7 8   f D o n e  pr e -v a c ci n ati o n;  o n  D a y  [ADDRESS_1089923] et e d  
* Gr o u p  4  o nl y  
P X V X -C V -3 1 7 -0 0 1  P r ot o c ol  V 4. 0  2 2 M a y 2 0 2 0  C O N FI D E N TI A L  P a g e  7 6   of  7 8   A P P E N DI X  C:   T O XI CI T Y  G R A DI N G  S C A L E  
 
 
 
E V E N T   
MI L D ( G r a d e  1)   
M O D E R A T E ( G r a d e  2)   
S E V E R E ( G r a d e  3)  P O T E N TI A L L Y  LI F E 
T H R E A T E NI N G ( G r a d e  4)  
F e v er  >  1 0 0. 4  –  1 0 1. 1 ° F 
(≥  3 8. 0  –  3 8. 4 ° C)  >  1 0 1. 2  –  1 0 2 ° F 
(≥  3 8. 5  –  <  3 9 ° C)  >  1 0 2. 1 ° F  –  1 0 4 ° F 
(≥  3 9 ° C  –  4 0 ° C)  >  1 0 4 ° F 
( >  4 0 ° C) 
H e a d a c h e  N o i nt erf er e n c e  wit h  a cti vit y   S o m e i nt erf er e n c e  wit h  a cti vit y, 
m a y r e q uir e r e p e at e d  us e  of  n o n - 
n ar c oti c  p ai n r eli e v er f or  m or e 
t h a n  2 4  h o urs Si g nifi c a nt,  pr e v e nts  d ail y 
a cti vit y,  a n y  us e  of  n ar c oti c  p ai n 
r eli e v er E R  visit  or  h os pit ali z ati o n  
F ati g u e  N o i nt erf er e n c e  wit h  a cti vit y   S o m e i nt erf er e n c e  wit h  a cti vit y   Si g nifi c a nt,  pr e v e nts  d ail y 
a cti vit y  E R  visit  or  h os pit ali z ati o n  
M y al gi a  N o i nt erf er e n c e  wit h  a cti vit y   S o m e i nt erf er e n c e  wit h  a cti vit y  Si g nifi c a nt,  pr e v e nts  d ail y 
a cti vit y  E R  visit  or  h os pit ali z ati o n  
N a us e a  N o i nt erf er e n c e  wit h  a cti vit y   S o m e i nt erf er e n c e  wit h  a cti vit y   Si g nifi c a nt,  pr e v e nts  d ail y 
a cti vit y  E R  visit  or  h os pit ali z ati o n f or 
h y p ot e nsi v e s h o c k  
V o miti n g  1 – 2  e pis o d es/ 2 4  h o urs  >  2  e pis o d es/ [ADDRESS_1089924] ati o n  E R  visit  or  h os pit ali z ati o n f or 
h y p ot e nsi v e s h o c k  
Di arr h e a  2  –  [ADDRESS_1089925] o ols  or  <  4 0 0  g ms / 
2 4  h o urs  4  –  5 st o ols  or  4 0 0 -8 0 0  g ms/ [ADDRESS_1089926] o ols  or  >  8 0 0 
g ms/ [ADDRESS_1089927] ati o n  E R  visit  or  h os pit ali z ati o n  
I nj e cti o n sit e  p ai n  D o es  n ot i nt erf er e  wit h  a cti vit y   R e p e at e d  us e  of  n o n -n ar c oti c  p ai n 
r eli e v er  >  2 4  h o urs  or i nt erf er es 
wit h  a cti vit y  Us e  of  a n y  n ar c oti c  p ai n r eli e v er 
or  pr e v e nts  d ail y  a cti vit y  E R  visit  or  h os pit ali z ati o n  
I nj e cti o n sit e er yt h e m a/r e d n ess  2 5 -5 0  m m  > 5 0  m m  –  1 0 0  m m  >  1 0 0  m m  N e cr osis  or  e xf oli ati v e  d er m atitis  
I nj e cti o n sit e i n d ur ati o n/s w elli n g 2 5 -5 0  m m  
a n d  d o es  n ot i nt erf er e  wit h 
a cti vit y  > 5 0  m m  –  1 0 0  m m  
or i nt erf er es  wit h  a cti vit y  >  1 0 0  m m  
or  pr e v e nts  d ail y  a cti vit y  N e cr osis  
H g b ( d e cr e as e fr o m b as eli n e  v al u e i n  g m/ d L)  F E M A L E:  A n y  d e cr e as e  –  1. 5 
M A L E:   A n y  d e cr e as e  –  1. 5  F E M A L E:   > 1. 5   – 2. 0  
M A L E:   > 1. 5 –  2. 0  F E M A L E:   > 2. 0   – 5. 0  
M A L E:   > 2. 0   – 5. 0  F E M A L E:   >  5. 0  
M A L E:    > 5. 0  
W B C i n cr e as e d  1 0, 8 0 0  –  1 5, 0 0 0  c ells/ m m
3 >  1 5, 0 0 0  –  2 0, 0 0 0  c ells/ m m3 >  2 0, 0 0 0  –  2 5, 0 0 0  c ells/ m m3 >  2 5, 0 0 0  c ells/ m m3 
W B C  d e cr e as e d  2 5 0 0  –  3 5 0 0  c ells/ m m3 1 5 0 0  –  <  2 5 0 0  c ells/ m m3 1 0 0 0  –  <  1 5 0 0  c ells/ m m3 <  1 0 0 0  c ells/ m m3 
L y m p h o c yt es  d e cr e as e d   7 5 0  –  1 0 0 0  c ells/ m m3 5 0 0  –  <  7 5 0  c ells/ m m3 2 5 0  –  <  5 0 0  c ells/ m m3 <  2 5 0  c ells/ m m3 
( c o nt’ d) 
P X V X -C V -3 1 7 -0 0 1  P r ot o c ol  V 4. 0  2 2 M a y 2 0 2 0  C O N FI D E N TI A L  P a g e  7 7   of  7 8   A P P E N DI X  C:   T O XI CI T Y  G R A DI N G  S C A L E  ( c o nt’ d) 
 
 
 
E V E N T   
MI L D ( G r a d e  1)   
M O D E R A T E ( G r a d e  2)   
S E V E R E ( G r a d e  3)  P O T E N TI A L L Y  LI F E 
T H R E A T E NI N G ( G r a d e  4)  
N e utr o p hils  d e cr e as e d  1 5 0 0  –  2 0 0 0  c ells/ m m3 1 0 0 0  –  <  1 5 0 0  c ells/ m m3 5 0 0  –  <  1 0 0 0  c ells/ m m3 <  5 0 0  c ells/ m m3 
Pl at el ets  1 2 5, 0 0 0  –  1 4 0, 0 0 0  c ells/ m m3 1 0 0, 0 0 0  –  <  1 2 5, 0 0 0  c ells/ m m3 2 5, 0 0 0  –  <  1 0 0, 0 0 0  c ells/ m m3 <  2 5, 0 0 0  c ells/ m m3 
Li v er f u n cti o n t ests 
( A S T,  A L T) 1. 1  –  2. 5  ×  U L N  >  2. 5  –  5. 0  ×  U L N  >  5  –  1 0  ×  U L N  >  1 0  ×  U L N  
Al k ali n e  p h os p h at as e  1. 1  –  2. 0  ×  U L N  >  2  –  3. 0  ×  U L N  >  3  –  1 0. 0  ×  U L N  >  1 0  ×  U L N  
Al b u mi n  2. 8  –  3. 1  g/ d L  2. 5  –  <  2. 8  g/ d L  <  2. 5  g/ d L  – –  
Bilir u bi n  –  wit h i n cr e as e d  L F Ts 1. 1  –  1. 2 5  ×  U L N  >  1. 2 5  –  1. 5  ×  U L N  >  1. 5  –  1. 7 5  ×  U L N  >  1. 7 5  ×  U L N  
Bilir u bi n  –  wit h  n or m al L F Ts  1. 1  –  1. 5  ×  U L N  > 1. 5  –  2. 0  ×  U L N  >  2. 0  –  3. 0  ×  U L N  >  3. 0  ×  U L N  
S o di u m  – H y p o n atr e mi a   1 3 2  –  1 3 4  m E q/ L  1 3 0  –  < 1 3 2  m E q/ L  1 2 5  –  <  1 3 0  m E q/ L  <  1 2 5  m E q/ L  
S o di u m  – H y p er n atr e mi a  1 4 4  –  1 4 5  m E q/ L  >  1 4 5  –  1 4 7  m E q/ L  >  1 4 7  –  1 5 0  m E q/ L  >  1 5 0  m E q/ L  
P ot assi u m  – 
H y p er k al e mi a  5. 1  –  5. 2  m E q/ L  >  5. 2  –  5. 4  m E q/ L  >  5. 4  –  5. 6  m E q/ L  >  5. 6  m E q/ L  
P ot assi u m  – 
H y p o k al e mi a  3. 5  –  3. 6  m E q/ L  3. 3  –  <  3. 5  m E q/ L  3. 1  –  <  3. 3  m E q/ L  <  3. 1  m E q/ L  
Bl o o d  Ur e a  Nitr o g e n ( B U N) 2 3  –  2 6  m g/ d L  >  2 6  –  3 1  m g/ d L  >  3 1  m g/ d L  R e q uir es  di al ysis  
S er u m  cr e ati ni n e  1. 5  –  1. 7  m g/ d L  >  1. 7  –  2. 0  m g/ d L  >  2. 0  –  2. 5  m g/ d L   >  2. 5  m g/ d L  or r e q uir es  di al ysis  
Uri n e  pr ot ei n  Tr a c e  1 +  2 +  H os pit ali z ati o n  or  di al ysis  
Uri n e  gl u c os e  Tr a c e  1 +  2 +  H os p. f or  h y p er gl y c e mi a  
 
 
Uri n e  bl o o d ( R B C/ h pf)b 1 – 1 0 ( cl e a n  c at c h, 
n ot  m e nstr u ati n g)  1 1 – 5 0 ( cl e a n  c at c h, 
n ot  m e nstr u ati n g)  >  5 0  a n d/ or  gr oss  bl o o d   
H os pit ali z ati o n  or  p a c k e d r e d 
bl o o d  c ells ( P R B C) tr a nsf usi o n  1 – 1 0 ( cl e a n  c at c h,  F)  1 1 – 5 0 ( cl e a n  c at c h,  F)   
>  5 0  a n d/ or  gr oss  bl o o d  
1 – 1 0 ( M)  1 1 – 5 0 ( M)  
L L N  =  L o w er li mit  of  n or m al.  U L N  =  U p p er li mit  of  n or m al. bA  p ositi v e t est f or  bl o o d  will  n ot  b e  c o nsi d er e d  Cli ni c all y  Si g nifi c a nt i n  a f e m al e s u bj e ct  w h o is  m e nstr u ati n g,  a n d 
mi cr os c o pi c  a n al ysis  will  n ot  b e  p erf or m e d  u nl ess  cli ni c all y i n di c at e d. If t h e s u bj e ct is  n ot  m e nstr u ati n g  a r e p e at  Uri n e  A n al ysis  will  b e  p erf or m e d.  
W h e n  d e v el o pi n g t his  T o xi cit y  Gr a di n g  S c al e,  E m er g e nt  Tr a v el  H e alt h r ef err e d t o t h e r e c o m m e n d ati o ns i n t h e  F D A’s  G ui d a n c e f or  I n d ustr y:  T o xi cit y  Gr a di n g  S c al e f or  H e alt h y 
A d ult  a n d  A d ol es c e nt  S u bj e cts  E nr oll e d i n  Pr e v e nti v e  V a c ci n e  Cli ni c al  Tri als ( 2 0 0 7)  a n d  a dj ust e d s o m e  p ar a m et ers t o  cl os e  g a ps  b et w e e n t h e t o xi cit y  gr a d es.  
 R E F E R E N C E S  
 
B or g h eri ni,  G.,  P o u b e a u,  P.,  St ai k o ws k y,  F.,  L or y,  M.,  L e  M o ull e c,  N.,  B e c q u art, J.  P., ...  &  P a g a ni n, 
F. ( 2 0 0 7).  O ut br e a k  of  c hi k u n g u n y a  o n  R e u ni o n Isl a n d:  e arl y  cli ni c al  a n d l a b or at or y f e at ur es i n  1 5 7 
a d ult  p ati e nts.  Cli ni c al I nf e cti o us  Dis e as es,  4 4( 1 1),  1 4 0 1 - 1 4 0 7. 
 
C e nt ers f or  Dis e as e  C o ntr ol ( 2 0 1 7).  G e o gr a p hi c  distri b uti o n  of  C hi k u n g u n y a  Vir us.  At 
htt ps:// w w w. c d c. g o v/ c hi k u n g u n y a/ g e o/i n d e x. ht ml , a c c ess e d  [ADDRESS_1089928] u m m er,  S.  H., ...  &  B ail er,  R. 
T. ( 2 0 1 4).  S af et y  a n d t ol er a bilit y  of  c hi k u n g u n y a  vir us- li k e  p arti cl e  v a c ci n e i n  h e alt h y  a d ults:  a  p h as e 
1  d os e- es c al ati o n tri al.  T h e  L a n c et,  3 8 4( 9 9 5 9),  2 0 4 6- 2 0 5 2. 
 
Pi [CONTACT_59207] o u x,  G.,  G a ü z èr e,  B.  A., J a ur é g ui b err y,  S.,  &  Str o b el,  M. ( 2 0 0 7).  C hi k u n g u n y a,  a n  e pi d e mi c 
ar b o vir osis.  T h e  L a n c et i nf e cti o us  dis e as es,  7( 5),  3 1 9- 3 2 7. 
 
P o w ers,  A.  M.,  &  L o g u e,  C.  H. ( 2 0 0 7).  C h a n gi n g  p att er ns  of  c hi k u n g u n y a  vir us: r e- e m er g e n c e  of  a 
z o o n oti c  ar b o vir us. J o ur n al  of  G e n er al  Vir ol o g y,  8 8( 9),  2 3 6 3- 2 3 7 7. 
 
R oss,  R.  W. ( 1 9 5 6).  T h e  N e w al a  e pi d e mi c: III.  T h e  vir us: is ol ati o n,  p at h o g e ni c  pr o p erti es  a n d 
r el ati o ns hi p t o t h e  e pi d e mi c.  E pi d e mi ol o g y  & I nf e cti o n,  5 4( 2),  [ADDRESS_1089929] es J E,  Hills,  S L  a n d  P o w ers  A M. ( 2 0 1 6).  C hi k u n g u n y a.  C h a pt er  3, C D C  Y ell o w  B o o k  a c c ess e d 
at  htt ps:// w w w n c. c d c. g o v/tr a v el/ y ell o w b o o k/ 2 0 1 6/i nf e cti o us- dis e as es -r el at e d-t o-tr a v el/ c hi k u n g u n y a 
o n  [ADDRESS_1089930] e n,  C.,  D o bl er,  G., ...  &  L ös c h er,  T. ( 2 0 0 7). C hi k u n g u n y a f e v er i n tr a v el ers:  cli ni c al  pr es e nt ati o n  a n d  c o urs e.  Cli ni c al I nf e cti o us  Dis e as es,  4 5( 1), e 1 - e 4. 
 
Y o o n, I.  K.,  Al er a,  M.  T.,  L a g o,  C.  B.,  T a c- A n, I.  A.,  Vill a,  D.,  F er n a n d e z,  S., ...  &  R o q u e Jr,  V.  G. ( 2 0 1 5).  Hi g h r at e  of s u b cli ni c al  c hi k u n g u n y a  vir us i nf e cti o n  a n d  ass o ci ati o n  of  n e utr ali zi n g  a nti b o d y 
wit h  pr ot e cti o n i n  a  pr os p e cti v e  c o h ort i n t h e  P hili p pi n es.  P L o S  N e gl  Tr o p  Dis,  9( 5),  e 0 0 0 3 7 6 4. 
 
 
    
 
     
 
   
 
P X V X -C V -3 1 7 -0 0 1  P r ot o c ol  V 4. 0  2 2 M a y 2 0 2 0   C O N FI D E N TI A L  P a g e  7 8  of  7 8  